Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2015 | Mar. 01, 2016 | Jun. 30, 2015 | |
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Period End Date | Dec. 31, 2015 | ||
Trading Symbol | nhc | ||
Entity Registrant Name | Nobilis Health Corp. | ||
Entity Central Index Key | 1,409,916 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Filer Category | Smaller Reporting Company | ||
Entity Common Stock, Shares Outstanding | 75,555,978 | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Well Known Seasoned Issuer | No | ||
Entity Public Float | $ 326,359,696 | ||
Document Fiscal Year Focus | 2,015 | ||
Document Fiscal Period Focus | FY |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 |
Current Assets: | ||
Cash | $ 15,666 | $ 7,568 |
Trade accounts receivable, net | 92,569 | 40,461 |
Medical supplies | 4,493 | 1,412 |
Prepaid expenses and other current assets | 2,789 | 3,554 |
Total current assets | 115,517 | 52,995 |
Property and equipment, net | 35,303 | 9,087 |
Intangible assets, net | 19,619 | 19,888 |
Goodwill | 44,833 | 21,589 |
Deferred tax asset | 25,035 | 0 |
Other long-term assets | 1,720 | 1,773 |
Total Assets | 242,027 | 105,332 |
Current Liabilities: | ||
Trade accounts payable | 23,381 | 10,528 |
Accrued expenses | 16,648 | 8,558 |
Lines of credit | 0 | 5,420 |
Subordinated notes payable | 0 | 635 |
Current portion of warrant and stock option derivative liabilities | 332 | 300 |
Current portion of long-term debt | 1,243 | 3,437 |
Current portion of capital leases | 5,193 | 257 |
Other current liabilities | 5,025 | 1,508 |
Total current liabilities | 51,822 | 30,643 |
Long-term capital leases, net of current portion | 13,654 | 573 |
Lines of credit | 3,000 | 0 |
Long-term debt, net of current portion | 21,469 | 10,582 |
Warrant and stock option derivative liabilities, net of current portion | 2,619 | 6,357 |
Other long-term liabilities | 3,386 | 508 |
Total liabilities | 95,950 | 48,663 |
Contingently redeemable noncontrolling interest | 12,225 | 12,867 |
Shareholders' Equity: | ||
Common stock (no par value; authorized unlimited shares, 73,675,979 and 59,418,227 shares issued and outstanding, respectively) | 0 | 0 |
Additional paid in capital | 211,827 | 176,356 |
Accumulated deficit | (85,491) | (136,687) |
Total shareholders' equity attributable to Nobilis Health Corp. | 126,336 | 39,669 |
Noncontrolling interests | 7,516 | 4,133 |
Total shareholders' equity | 133,852 | 43,802 |
Total Liabilities and Shareholders' Equity | $ 242,027 | $ 105,332 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Dec. 31, 2015 | Dec. 31, 2014 |
Common Stock, No Par Value | ||
Common Stock, Shares, Issued | 73,675,979 | 59,418,227 |
Common Stock, Shares, Outstanding | 73,675,979 | 59,418,227 |
Consolidated Statements of Earn
Consolidated Statements of Earnings - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Revenues: | ||
Patient and net professional fees | $ 209,446 | $ 80,917 |
Contracted marketing revenues | 13,106 | 2,171 |
Factoring revenues | 6,664 | 941 |
Total revenue | 229,216 | 84,029 |
Provision for bad debts | 3,557 | 0 |
Income from operations | 31,650 | 20,491 |
Other (income) expense: | ||
Change in fair value of warrant and stock option derivative liabilities | (8,985) | 3,721 |
Interest expense | 1,597 | 288 |
Bargain purchase gain | (1,733) | 0 |
Other expense, net | 34 | 32 |
Total other (income) expense | (9,087) | 4,041 |
Income before income taxes and noncontrolling interests | 40,737 | 16,450 |
Income tax expense | 1,839 | 480 |
Income tax benefit | (25,035) | 0 |
Net income | 63,933 | 15,970 |
Net income attributable to noncontrolling interests | 13,093 | 13,077 |
Net income attributable to Nobilis Health Corp. | $ 50,840 | $ 2,893 |
Net income per basic common share | $ 0.76 | $ 0.06 |
Net income per fully diluted common share | $ 0.68 | $ 0.06 |
Weighted average shares outstanding (basic) | 67,015,387 | 46,517,815 |
Weighted average shares outstanding (fully diluted) | 75,232,783 | 47,720,569 |
Operating expenses [Member] | ||
Revenues: | ||
Salaries and benefits | $ 40,845 | $ 11,933 |
Drugs and supplies | 37,365 | 11,295 |
General and administrative | 79,422 | 31,792 |
Provision for bad debts | 3,557 | 0 |
Depreciation | 4,531 | 1,503 |
Total corporate costs | 165,720 | 56,523 |
Corporate costs [Member] | ||
Revenues: | ||
Salaries and benefits | 6,597 | 2,386 |
General and administrative | 22,648 | 4,449 |
Legal expenses | 2,445 | 66 |
Depreciation | 156 | 114 |
Total corporate costs | $ 31,846 | $ 7,015 |
Consolidated Statements of Chan
Consolidated Statements of Changes in Equity - USD ($) | Common Stock [Member] | Additional Paid In Capital (Restated) [Member] | Accumulated Deficit (Restated) [Member] | Equity Attibutable to Nobilis Health (Restated) [Member] | Equity Attributable to Noncontrolling Interests (Restated) [Member] | Total |
Beginning Balance at Dec. 31, 2013 | $ 148,128 | $ (139,580) | $ 8,548 | $ 3,491 | $ 12,039 | |
Beginning Balance (Shares) at Dec. 31, 2013 | 42,729,547 | |||||
Net income | 2,893 | 2,893 | 3,833 | 6,726 | ||
Proceeds from private equity offering | 3,956 | 3,956 | 3,956 | |||
Proceeds from private equity offering (Shares) | 5,568,400 | |||||
Sale of ownership interest in subsidiary | 705 | 705 | 705 | |||
Purchase of investment | 490 | 490 | 490 | |||
Purchase of investment (Shares) | 431,711 | |||||
Consolidation of investment | 522 | 522 | ||||
Acquisition of Athas Health | 16,239 | 16,239 | 16,239 | |||
Acquisition of Athas Health (Shares) | 6,666,666 | |||||
Distributions to noncontrolling interests | (3,713) | (3,713) | ||||
Vesting of restricted stock (Shares) | 215,896 | |||||
Exercise of stock warrants | 4,797 | 4,797 | 4,797 | |||
Exercise of stock warrants (Shares) | 3,206,007 | |||||
Exercise of stock options | 166 | 166 | 166 | |||
Exercise of stock options (Shares) | 600,000 | |||||
Share-based compensation | 1,875 | 1,875 | 1,875 | |||
Ending Balance at Dec. 31, 2014 | 176,356 | (136,687) | 39,669 | 4,133 | 43,802 | |
Ending Balance (Shares) at Dec. 31, 2014 | 59,418,227 | |||||
Net income | 50,840 | 50,840 | 2,226 | 53,066 | ||
Deconsolidation of investment | (613) | 356 | (257) | 307 | 50 | |
Proceeds from private equity offering | 15,598 | 15,598 | 15,598 | |||
Proceeds from private equity offering (Shares) | 4,029,668 | |||||
Acquisition of Peak | 650 | 650 | 650 | |||
Acquisition of Peak (Shares) | 89,749 | |||||
Acquisition of Scottsdale Liberty | 1,532 | 1,532 | ||||
Athas settlement | (5,685) | (5,685) | (5,685) | |||
Athas settlement (Shares) | 3,830,638 | |||||
Measurement period adjustments | 2,807 | 2,807 | ||||
Sale of ownership interest in subsidiary | 0 | |||||
Distributions to noncontrolling interests | (3,489) | (3,489) | ||||
Vesting of restricted stock (Shares) | 2,725,000 | |||||
Reclassification of vested non-employee | (1,531) | (1,531) | (1,531) | |||
Exercise of stock warrants | 13,392 | 13,392 | 13,392 | |||
Exercise of stock warrants (Shares) | 3,134,909 | |||||
Exercise of stock options | 521 | 521 | 521 | |||
Exercise of stock options (Shares) | 447,788 | |||||
Share-based compensation | 13,139 | 13,139 | 13,139 | |||
Ending Balance at Dec. 31, 2015 | $ 211,827 | $ (85,491) | $ 126,336 | $ 7,516 | $ 133,852 | |
Ending Balance (Shares) at Dec. 31, 2015 | 73,675,979 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net income | $ 63,933 | $ 15,970 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Depreciation and amortization | 4,687 | 1,616 |
Provision for bad debts | 3,557 | 0 |
Share-based compensation | 13,139 | 1,875 |
Change in fair value of warrant and stock option derivative liabilities | (8,985) | 3,721 |
Deferred income taxes | (25,035) | 0 |
Impairment charges | 1,622 | 0 |
Recoupment Indemnified expenses | (1,700) | 0 |
Gain on sale of fixed asset | 0 | (39) |
Gain on bargain purchase of a business | (1,733) | 0 |
Amortization of deferred financing fees | 99 | 0 |
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed: | ||
Trade accounts receivable | (51,673) | (20,958) |
Medical supplies | (1,469) | (27) |
Prepaids and other current assets | 6,966 | (2,799) |
Other long-term assets | (402) | 466 |
Trade accounts payable and accrued liabilities | 925 | 2,841 |
Other current liabilities | 3,441 | 1,340 |
Other long-term liabilities | (657) | (8) |
Net cash provided by operating activities | 6,715 | 3,998 |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Purchase of property and equipment | (4,380) | (2,023) |
Investment in associate | (138) | (150) |
Note receivable | (197) | 0 |
Purchase of interest acquired in subsidiary | 0 | (346) |
Proceeds of sale of property and equipment | 0 | 39 |
Proceeds of sale of ownership interests in subsidiary | 0 | 705 |
Acquisition of Athas | 0 | (3,000) |
Acquisition of Hermann Drive, net of cash acquired | (1,436) | 0 |
Acquisition of Peak, net of cash acquired | (850) | 0 |
Acquisition of Marsh Lane, net of cash acquired | (1,299) | 0 |
Acquisition of Scottsdale Liberty | (3,180) | 0 |
Deconsolidation of imaging centers and urgent care clinic | (166) | 0 |
Net cash used for investing activities | (11,646) | (4,775) |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Distributions to non controlling interests | (14,998) | (6,559) |
Proceeds from exercise of stock options | 521 | 166 |
Proceeds from exercise of stock warrants | 4,342 | 3,188 |
Proceeds from private placement | 28,395 | 6,100 |
Payments on capital lease obligations | (1,565) | (77) |
Proceeds from line of credit | 4,500 | 1,300 |
Payments on line of credit | (6,920) | 0 |
Proceeds from debt | 20,000 | 0 |
Payments of debt | (20,584) | (1,375) |
Deferred financing fees | (662) | 0 |
Net cash provided by financing activities | 13,029 | 2,743 |
NET INCREASE IN CASH | 8,098 | 1,966 |
CASH — Beginning of year | 7,568 | 5,602 |
CASH — End of year | $ 15,666 | $ 7,568 |
Company Description
Company Description | 12 Months Ended |
Dec. 31, 2015 | |
Company Description [Text Block] | 1. Company Description Nobilis Health Corp. (“Nobilis” or the “Company”) was incorporated on March 16, 2007 under the name "Northstar Healthcare Inc." pursuant to the provisions of the British Columbia Business Corporations Act |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2015 | |
Summary of Significant Accounting Policies [Text Block] | 2. Summary of Significant Accounting Policies Basis of Presentation The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). Principles of Consolidation The Company consolidates entities in which it has a controlling financial interest. We consolidate subsidiaries in which we hold, directly or indirectly, more than 50% of the voting rights and, in the case of variable interest entities (“VIEs”), with respect to which the Company is determined to be the primary beneficiary. Noncontrolling Interests Variable Interest Entities Use of Accounting Estimates The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Estimates most consequential to our consolidated financial statements are in the area of revenue recognition. Because a significant portion of our net patient service revenue is associated with services provided on out-of-network basis, with no contractually agreed-upon reimbursement rates from third-party payors, revenues expected to be realized are estimated based on our historical experience with allowable charges by a given payor for the specific service performed. These estimates are subject to ongoing monitoring and adjustment based on actual experience with final settlements and collections. Other significant estimates include estimates of fair values which management formulates in connection with valuation of assets and liabilities acquired in business combinations and impairment tests of goodwill, intangible assets, property, and certain investments and financial instruments; estimates of useful lives of our property and intangible assets; as well as realizable amounts of accounts receivable and deferred tax assets. Revenue Recognition Patient and Net Professional Fees The amounts actually collected by the Company from third-party payors, including private insurers vary among payors, even for identical medical procedures. As such, in estimating net patient service revenues, management evaluates payor mix, (among private health insurance plans, workers’ compensation insurers, government payor plans and patients), historical settlement and payment data for a given payor and type of medical procedure, and current economic conditions and revises its revenue estimates as necessary in subsequent. For services subject to contracted rates with third-party payors, revenues are recognized net of applicable contractual adjustments. Contracted Marketing Revenues Factoring Revenues Advertising and Marketing Costs Advertising costs are expensed as they are incurred. Advertising expense for the years ended December 31, 2015 and 2014 was $35.0 million and $9.9 million, respectively. The Company utilizes many media outlets for marketing to patients which include internet, TV, radio, print, seminar and billboard advertising. Advertising and marketing expense is recorded within both the operating expenses: general and administrative and corporate costs: general and administrative line items within the consolidated statements of earnings. Cash We maintain our cash in bank deposit accounts that at times may exceed federally insured limits. At December 31, 2015 and 2014, our cash deposits exceeded such federally insured limits. We have not experienced any losses in such accounts, and we believe we are not exposed to any significant credit risks on cash. Trade Accounts Receivable, net Trade accounts receivable, net consists of net patient service revenues and factoring revenues recorded at their net realizable amounts, while contracted marketing revenues are recognized at the fees due from the facilities for marketing services performed pursuant to governing contractual arrangements. On a periodic basis, we evaluate receivables based on the age of the receivable, history of past collections and current credit and economic conditions and adjust the carrying amount accordingly. An account is written off when it is determined that all collection efforts have been exhausted. The Company does not accrue finance or interest charges on accounts receivable. An allowance for uncollectible patient receivables balances, including receivables from non-partner surgeons, is maintained at a level which the Company believes is adequate to absorb probable credit losses. Medical Supplies Medical supplies consist of various surgical supplies and medications and are carried at the lower of cost or market on the first-in, first-out method. The market value of inventories is determined based on the estimated selling price in the ordinary course of business less the estimated costs of sale, and a reasonable profit margin based on the effort required to sell the inventories. The Company had no write-downs in the carrying amounts of medical supplies inventories for the years ended December 31, 2015 or 2014. Property and Equipment Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets. Property under capital leases and the related obligation for future lease payments are initially recorded at an amount equal to the lesser of fair value of the property and equipment or the present value of the future lease payments. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense when incurred. We evaluate our long-lived assets for possible impairment annually or whenever events or changes in circumstances indicate that the carrying amount of the asset, or related group of assets, may not be recoverable from estimated future undiscounted cash flows expected to arise from their use and ultimate disposition. If the estimated future undiscounted cash flows are lower than the carrying amount of the assets, we determine the amount of impairment, if any, as the excess of the carrying amount of the long-lived asset over its estimated fair value. The fair value of the assets is estimated based on appraisals, established market values of comparable assets or internal estimates of discounted future net cash flows expected to result from the use and ultimate disposition of the asset. The estimates of these future cash flows are based on assumptions and projections we believe to be reasonable and supportable. They require our subjective judgments and take into account assumptions about revenue and expense growth rates. These assumptions may vary by type of facility and presume stable, improving or, in some cases, declining results at our medical facilities, depending on their specific operating circumstances. We report long-lived assets to be disposed of at the lower of their carrying amounts or fair values less costs to sell. In such circumstances, our estimates of fair value are based on appraisals, established market prices for comparable assets or internal estimates of future net cash flows. Gains and losses on disposals of property and equipment are determined by comparing the proceeds from disposal with the net carrying amount of property and equipment, and are recognized within other expense (income) in the consolidated statement of earnings. Goodwill and Intangibles Goodwill represents the excess of the cost of an acquired business over the acquisition-date fair value of the net identifiable assets acquired. Goodwill is reviewed for impairment on an annual basis or more frequently if events or circumstances indicate potential impairment. Such review is performed at the reporting unit level, whereby goodwill balances and identifiable assets and liabilities are assigned to a reporting unit to which they relate. For this purpose, the Company currently has two reporting units which are aligned with its business segments. The Company’s goodwill evaluation for each reporting unit is based on both qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying amount. The Company assesses qualitative factors to determine if the fair value of its reporting units is more likely than not to exceed its carrying amount, including goodwill. In the event the Company determines that it is more likely than not that a reporting unit’s fair value is lower than its carrying amount, quantitative testing is performed comparing carrying amount of the reporting unit to estimated fair value. Fair value estimates are based on appraisals, established market prices for comparable assets or internal estimates of discounted future net cash flows. If the fair value of the reporting unit exceeds the carrying amount, goodwill is not impaired. If the carrying amount exceeds the fair value, an impairment charge is recognized for the excess of the carrying amount of goodwill over its implied fair value. Indefinite-lived intangible assets consisting of trade names, trademarks, and Medicare and hospital licenses, are not amortizable; however, are evaluated for impairment on an annual basis. Intangible assets subject to amortization, which consist of non-compete agreements, lease contract intangibles, internally developed software, trade secret methodology and physician relationships, are carried at cost less accumulated amortization, which is calculated on a straight-line basis over a period of five to 20 years depending on the asset’s useful life. Investments in Unconsolidated Affiliates Investments in unconsolidated affiliates include the Company’s investments in non-marketable equity securities that do not represent a controlling financial interest in the investee. Such investment balances are included in the Company’s consolidated balance sheets in Other long-term assets, and include investments accounted for using the equity and the cost method of accounting. Where the Company exercises significant influence over the investee, the Company accounts for its investment under the equity method of accounting. In other cases, the investments in unconsolidated affiliates are accounted for using the cost method of accounting. Whether or not the Company exercises significant influence with respect to an investee depends on an evaluation of several factors including, among others, representation on the investee’s board of directors, ability to participate in setting operating, financial and other policies of the investee, and ownership level. Under the equity method of accounting, the carrying amount of the investment is adjusted each reporting period for the Company’s pro rata share of investee’s earnings (which also are reflected in other expense (income) in the Company’s consolidated statements of earnings) and any distributions received. Cost-method investments are stated at cost, adjusted only to reflect any other-than-temporary impairment in value or return of the capital invested through a distribution or disposition. Earnings on cost-method investments, if any, are recognized in other expense (income) when dividends or other distributions of earnings are declared. Investments in unconsolidated affiliates are reviewed for impairment at least annually and any impairment loss that is other than temporary is recognized in the consolidated statements of earnings, with no future recovery in value recognized. Income Taxes The tax expense for the period comprises current and deferred tax. Tax expense is recognized in the consolidated statement of earnings, except to the extent that it relates to items recognized directly in equity. For items recognized directly in equity, the tax expense is also recognized in equity. The current income tax charge is calculated on the basis of the tax laws enacted at the balance sheet date in the countries where the Company’s subsidiaries operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulations are subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities. Deferred income tax is recognized, using the liability method, on temporary differences arising between the tax base of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred income tax is determined using tax rates (and laws) that have been enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred income tax assets are recognized only to the extent that it is probable that future taxable profit against which the temporary difference can be utilized will be available. Deferred income tax is provided on temporary differences arising on investments in subsidiaries and unconsolidated affiliates, except where the timing of the reversal of the temporary difference is controlled by the Company and it is probable that the temporary difference will not reverse in the foreseeable future. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. The Company annually evaluates tax positions to determine the need for any additional disclosures, de-recognition, classification, interest and penalties on income taxes and accounting for income tax estimates in interim periods. In assessing the need for a valuation allowance, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Fair Value Certain financial instruments are reported at fair value on our consolidated balance sheets. Under fair value measurement accounting guidance, fair value is defined as the amount that would be received from the sale of an asset or paid for the transfer of a liability in an orderly transaction between market participants, (i.e., an exit price). To estimate an exit price, a three-level hierarchy is used. The fair value hierarchy prioritizes the inputs, which refer broadly to assumptions market participants would use in pricing an asset or a liability, into three levels. Level 1 inputs are unadjusted quoted prices in active markets for identical assets and liabilities and have the highest priority. Level 2 inputs are inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly (such as quoted prices for similar assets or liabilities). Level 3 inputs are unobservable inputs for the asset or liability and have the lowest priority (such as cash-flow assumptions formulated by management). The valuation techniques that may be used to measure fair value include a market approach, an income approach and a cost approach. A market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. An income approach uses valuation techniques to convert future cash flow amounts to a single present amount based on current market expectations, including present value techniques, option-pricing models and the excess earnings method. The cost approach is based on the amount that currently would be required to replace the service capacity of an asset (replacement cost). Leases Certain leases to which the Company is party as a lessee are classified as capital leases whenever the terms of the lease transfer to the Company substantially all of the risks and rewards of ownership. Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases (net of any incentives received from the lessor) are charged to the consolidated statement of earnings on a straight-line basis over the period of the lease as rent expense. Foreign Currency The Company has no significant business operations outside the United States and, therefore, the functional currency and the local currency for its business operations is the U.S. Dollar (“USD”). The accompanying consolidated statements are also presented in USD, the Company’s reporting currency. From time to time monetary assets and liabilities may be denominated in foreign currency, and, if so, will be translated at the exchange rate in effect as of the balance sheet date, with resulting gains or losses included within the consolidated statement of earnings. Revenues and expenses denominated in foreign currencies are translated into USD at the average foreign currency exchange rate for the period. Stock-Based Compensation The Company recognizes all stock-based compensation to employees, including grants of employee stock options, in the consolidated financial statements based on their grant-date fair values. The Company values its stock options awarded using the Black-Scholes option pricing model. Restricted stock awards are valued at the grant-date closing market price. Stock-based compensation costs are recognized over the vesting period, which is the period during which the employee is required to provide service in exchange for the award. Occasionally, the Company issues stock-based awards to non-employees. The fair value of these option awards is estimated when the award recipient completes the contracted professional services. The Company recognizes expense for the estimated total value of the awards during the period from their issuance until performance completion, at which time the estimated expense is adjusted to the final value of the award as measured at performance completion. Because our non-employee stock options were issued with exercise prices denominated in Canadian Dollars, upon performance completion, their fair values are reclassified from equity to liabilities and remeasured to fair value each reporting period, with remeasurement gains and losses recognized in other income (expense) in our consolidated statements of earnings. Net Income per Common Share We calculate net income per common share by dividing net income available for common shareholders by the weighted average number of common shares outstanding during the period. Fully diluted income per share is computed using the weighted average number of common and potential common shares outstanding during the period. Potential common shares include those that may be issued upon redemption of units granted under the Company’s restricted stock unit and Share Option Plans. Segment Reporting The Company reports segment information based on how the chief operating decision maker, along with other members of management, organize and utilize financial and operational data in determining how to allocate resources and assess performance. Effective December 1, 2014, the Company’s business lines are classified into two reportable business segments which include a medical services segment and a marketing and factoring segment. The medical services segment provides the operation of hospitals, outpatient facilities and other related health care services. The marketing and factoring segment provides direct-to-consumer marketing efforts which educate patients on their healthcare options. Factoring activities are included in the marketing segment, as such activities only pertain to patients services that result from the Company’s marketing efforts. We evaluate performance based on income from operations of the respective business segments prior to the allocation of corporate office expenses. Transactions between segments are eliminated in consolidation. Our corporate office provides general and administrative and support services to our two revenue-generating segments. Management allocates costs between segments for selling, general and administrative expenses and depreciation expense. Reclassifications and Corrections Certain amounts in the consolidated financial statements and these notes have been reclassified to conform to the current period presentation. Additionally, corrections were made to the 2014 financial statements to correct the presentation of foreign currency translation amounts to foreign currency transaction amounts and correct the presentation of the 2014 deferred tax inventory in Note 24. The reclassifications included in these comparative consolidated financial statements are (i) a reclassification of an unfavorable lease liability from intangible assets to other long-term liabilities, (ii) a balance sheet reclassification between property and equipment and accumulated depreciation of property and equipment. The reclassifications and corrections were deemed to be immaterial to the consolidated financial statements both individually and in the aggregate. The correction of other comprehensive income resulted in a decrease in 2014 net income of $0.2 million and a decrease in both basic and diluted earnings per share of $0.01. The correction of the deferred tax inventory had no impact on net income because of the full valuation allowance at December 31, 2014. Recent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09 “Revenue from Contracts with Customers” that provides a single, comprehensive revenue recognition model for all contracts with customers and supersedes current revenue recognition guidance. The revenue standard contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. On July 9, 2015, the FASB voted to approve a one-year deferral of the effective date. This new guidance is now effective for annual reporting periods beginning after December 15, 2017. The standard allows for either “full retrospective” adoption, meaning the standard is applied to all of the periods presented, or “modified retrospective” adoption, meaning the standard is applied only to the most current period presented in the financial statements, with the cumulative effect of initial disclosure of the effect of using this method of adoption on the financial statement line items. The Company is currently evaluating the new guidance to determine the method of adoption that it will use and the impact it will have on its consolidated financial statements. In June 2014, the FASB issued ASU No. 2014-12 “Compensation – Stock Compensation” that provides amended guidance on the accounting for certain share-based employee compensation awards. The amended guidance applies to share-based employee compensation awards that include a performance target that affects vesting when the performance target can be achieved after the requisite service period. These targets are to be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award and compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved. The amendments are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. The Company does not expect adoption will have a material impact on its consolidated financial statements. In February 2015, the FASB issued ASU No. 2015-02 “Consolidation (Topic 810): Amendments to the Consolidation Analysis” that amends the current consolidation guidance. The amendments affect both the variable interest entity and voting interest entity consolidation models. The guidance must be applied using one of two retrospective application methods and will be effective for fiscal years beginning after December 15, 2015, and for interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The Company does not expect adoption will have a material impact on its consolidated financial statements. In April 2015, the FASB issued ASU No. 2015-03 “Simplifying the Presentation of Debt Issuance Costs,” which requires that debt issuance costs be presented in the balance sheet as a direct deduction from the carrying amount of related debt liability, consistent with debt discounts. Under the former accounting standards, such costs were recorded as an asset. On August 18, 2015, the FASB clarified that the guidance in ASU No. 2015-03 does not apply to line-of-credit arrangements. Accordingly, companies may continue to present debt issuance costs for line-of-credit arrangements as an asset and subsequently amortize the deferred debt costs ratably over the term of the arrangement. This new guidance is effective for annual reporting periods beginning after December 15, 2015. The Company adopted this ASU in the second quarter of 2015. In July 2015, the FASB issued ASU No. 2015-11 “Inventory (Topic 330): Simplifying the Measurement of Inventory,” which requires inventory measured using the FIFO or average cost methods to be subsequently measured at the lower of cost and net realizable value. The new guidance is effective for annual reporting periods beginning after December 15, 2016, with early adoption permitted. This new guidance is not expected to have a material impact on the Company’s consolidated financial statements. In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, requiring that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. This ASU also requires an entity to present separately on the face of the income statement, or disclose in the notes to the financial statements, the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. This ASU is effective within annual periods beginning on or after December 15, 2015, including interim periods within that reporting period, and will be applied prospectively to measurement period adjustments that occur after the effective date of this ASU. The Company adopted this ASU in the third quarter of 2015. In November 2015, the FASB issued ASU No. 2015-17 “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes,” which simplifies the presentation of deferred income taxes. Under the new accounting standard, deferred tax assets and liabilities are required to be classified as noncurrent, eliminating the prior requirement to separate deferred tax assets and liabilities into current and noncurrent. The new guidance is effective for annual reporting periods beginning after December 15, 2016, with early adoption permitted. The standard may be adopted prospectively or retrospectively to all periods presented. The Company is currently assessing the timing of adoption of the new guidance, but does not expect it will have a material impact on the Company’s consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) which supersedes FASB ASC Topic 840, Leases (Topic 840) and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted upon issuance. The Company is currently evaluating the method of adoption and the impact of adopting ASU 2016-02 on its results of operations, cash flows and financial position. |
Supplemental Cash Flow Informat
Supplemental Cash Flow Information | 12 Months Ended |
Dec. 31, 2015 | |
Supplemental Cash Flow Information [Text Block] | 3. Supplemental Cash Flow Information The changes in operating assets and liabilities for the years-ended December 31, 2015 and 2014 are comprised of the following (in thousands): 2015 2014 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid for interest $ 1,236 $ 165 Cash paid for taxes $ 427 $ 216 SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Non-cash acquisition of property and equipment $ 28,373 $ 2,271 Non-cash acquisition of goodwill and intagibles $ 24,641 $ 7,206 Non-cash deconsolidation of property and equipment $ 2,828 $ - Non-cash deconsolidation of goodwill $ 701 $ - Non-cash purchase of medical equipment through capital lease $ - $ 696 Stock consideration given for purchase of interest in subsidiary $ 650 $ - Athas settlement in lieu of contingent shares $ 5,685 $ - |
Acquisitions and Business Combi
Acquisitions and Business Combinations | 12 Months Ended |
Dec. 31, 2015 | |
Acquisitions and Business Combinations [Text Block] | 4. Acquisitions and Business Combinations Imaging Centers and Urgent Care Clinic In January 2014, the Company acquired an ownership interest in two imaging centers and one urgent care clinic in Houston. The Company acquired a 32.14% interest in Spring Northwest Operating, LLC, a 31.78% interest in Spring Northwest Management, LLC and a 22.22% interest in Willowbrook Imaging, LLC. The aggregate cost of the acquisition is comprised of $0.3 million in cash, net of acquired cash, and 431,711 shares of Nobilis stock representing a combined value of $1.4 million. As a result of the acquisition, the Company recognized $0.7 million of goodwill within our medical services segment which is deductible for tax purposes. The Company believes that the goodwill is primarily comprised of the ability to further diversify the Company’s revenue stream while creating a valuable presence in the Northwest region of the Houston, Texas market. Effective January 1, 2015, these entities were deconsolidated. Refer to Note 5. The following table summarizes the fair values of the identifiable assets acquired and liabilities assumed at the date of acquisition (in thousands): January 16, 2014 Net assets acquired: Cash $ 563 Prepaid expenses 48 Property and equipment 2,271 Other assets 40 Goodwill 701 Net assets acquired $ 3,623 Net liabilities assumed: Accounts payable $ 697 Debt 1,544 Net liabilities assumed $ 2,241 Consideration: Cash, net of cash acquired $ 346 Stock issued for acquisition 514 Noncontrolling interest 522 Total Consideration $ 1,382 First Nobilis, LLC In September 2014, the Company formed First Nobilis, a Texas limited liability company. First Nobilis is owned 51% by the Company and 49% by a third party. First Nobilis formed two subsidiary Texas limited liability companies to be the new operating entities. Upon formation of First Nobilis, effective September 1, 2014, Nobilis contributed $7.5 million in cash to the new entity. For a 49% ownership interest, a third party contributed medical supplies, intangible assets and certain accounts payables and accounts receivables. As part of the transaction, certain of the Company’s assets were used as collateral on lines of credit for the landlord which were satisfied in December 2015. The Company entered into the First Nobilis arrangement in order to establish its first hospital platform in the Houston market for serving a broader patient population with higher acuity. As a result of the acquisition, the Company recognized $0.6 million of goodwill within our medical services segment which is deductible for tax purposes. As the transaction has resulted in the Company’s first acute care facility in the Houston market, the Company believes that the goodwill is primarily comprised of our enhanced service option to provide patients with a higher acuity of care. The fair value of the noncontrolling interest was also determined using both Level 2 inputs, which include observable market data other than quoted prices, and Level 3 inputs, which include unobservable data. The implied noncontrolling interest value, as calculated using the implied equity value of the Company and the 49% minority interest percentage, was discounted for both lack of control and lack of marketability using various inputs, including volatility, certain market control premiums from similar market transactions and the estimated amount of time it would take to sell the equity in the market without affecting the price. The following table summarizes the fair values of the identifiable assets acquired and liabilities assumed at the date of acquisition ( in thousands) September 2014 Net assets acquired: Accounts receivable $ 6,509 Inventory 598 Trade name 1,000 Physician relationships 2,800 Goodwill 649 Net assets acquired $ 11,556 Net liabilities assumed: Accounts payable $ 6,060 Unfavorable lease 290 Total liabilities assumed $ 6,350 Consideration: 49% ownership interest $ 5,206 Athas Health, LLC (“Athas”) In December 2014, the Company completed its acquisition of Athas for total consideration of approximately $31.2 million consisting of $3.0 million in cash upon closing, a promissory note by Nobilis to the sellers of $12.0 million, 6,666,666 shares of Nobilis common stock that are subject to a lock up period of up to two years and the issuance of an additional 4,666,666 shares of Nobilis common stock issued over two years, with half issued on the first anniversary of the closing and the second half issued on the second anniversary of the closing. Under the two year lock up period, the stock issued as part of the purchase price is subject to restrictions on transfer and may not be sold or pledged until the lock up period is released. Athas is based in Dallas, Texas, and focuses on the delivery of specialized healthcare services in seven states through the use of contracted marketing services and factoring of receivables. They are a nationwide direct-to-consumer marketing company with multiple established campaigns in various clinical service lines. Through the acquisition of Athas, the Company is able to vastly expand its marketing infrastructure. The fair value of the stock issued for consideration was also determined using both Level 1 inputs, which include quoted market prices, and Level 2 inputs, which include observable data other than quoted prices. The value was determined using the published stock price on the date of closing, less a discount for lack of marketability as a result of the two year lock up period on the shares issued. The discount for lack of marketability was calculated using observable volatility rates from comparable companies, quoted risk free rates and the expected holding period as a result of the two year lock up period. The discount for lack of marketability ranges from 18% to 30%. As a result of the acquisition, the Company recognized $19.0 million of goodwill within our marketing segment which is deductible for tax purposes. The Company believes that the goodwill is primarily comprised of the potential benefit of having a marketing platform with proprietary technology in customer relation management that further distinguishes us from other healthcare providers, in addition to being able to enhance our marketing capabilities by broadening the Company’s reach to new patient markets. The following table summarizes the fair values of the identifiable assets acquired and liabilities assumed at the date of acquisition ( in thousands) December 2014 Net assets acquired: Cash $ (53 ) Trade accounts receivable 4,713 Other receivable 450 Prepaid expenses 226 Investment in associate 730 PP&E 752 Trademark 5,610 Internally developed software 1,980 Non-compete agreements 1,920 Trade secret medical technology 5,620 Goodwill 19,011 Net assets acquired $ 40,959 Net liabilities assumed: Trade accounts payable $ 1,531 Accrued liabilities 2,915 Line of credit 4,120 Subordinated notes payable 635 Note payable 157 Other current liabilities 102 Other long-term liabilities 260 Total liabilities assumed $ 9,720 Consideration: Cash, net of cash acquired $ 3,000 Debt issued for consideration 12,000 Stock issued for consideration 16,239 Total consideration $ 31,239 Hermann Drive Surgical Hospital (“Hermann Drive”) (f/k/a Victory Medical Center Houston) In April 2015, the Company acquired a 55% ownership interest in Victory Medical Center Houston, L.P. (n/k/a Hermann Drive Surgical Hospital, LP), which owns and operates Victory Healthcare Houston Hospital (n/k/a Hermann Drive Surgical Hospital), a surgical hospital located in the Texas Medical Center in Houston, Texas. The Company acquired its ownership percentage for cash consideration of $1.4 million and assumed certain leases and loans of Hermann Drive. The acquisition of Hermann Drive provides the Company with managed care contracts spread across several major insurance carriers. Through this acquisition, the Company will also establish greater geographical coverage with this facility being located in the Texas Medical Center with a group of established physician partners. As a result of the acquisition, the Company has recognized $16.0 million of goodwill within our medical services segment which is deductible for tax purposes. The Company believes that the goodwill is primarily comprised of the business opportunities to be gained through the expanded geographical coverage as well as the access to a new physician group. In addition, the managed care contracts at this facility allow the Company to offer its services to a broader market segment. The fair value of the noncontrolling interest was also determined using both Level 2 inputs, which include observable market data other than quoted prices and Level 3 inputs, which include unobservable data. The implied noncontrolling interest value, as calculated using the implied equity value of the Company and the 45% minority interest percentage, was discounted for both lack of control and lack of marketability using various inputs, including volatility, certain market control premiums from similar market transactions and the estimated amount of time it would take to sell the equity in the market without affecting the price. Subsequent to the acquisition date of April 24, 2015, Hermann Drive had $12.5 million in revenues and a loss of $1.5 million which is included in the Company’s consolidated statement of earnings for the year ended December 31, 2015. The costs related to the transaction were nominal and were expensed during the year ended December 31, 2015. These costs are included in the corporate general and administrative expenses in the Company’s consolidated statement of earnings for the year ended December 31, 2015. During the measurement period, management determined certain adjustments to the acquired assets and liabilities which are detailed in the table below. FASB Accounting Standards Codification 805, “Business Combinations”, as amended by ASU 2015-16, requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. During the year ended December 31, 2015, the Company made the adjustments specified below with a corresponding adjustment to goodwill, and with no material effect on previous-period or current-period earnings. The following table summarizes the fair values of the identifiable assets acquired and liabilities assumed at the date of acquisition ( in thousands As Previously Measurement Period Determined Adjustments Revised Net assets acquired: Cash $ 64 $ - $ 64 Trade accounts receivable 2,500 (364 ) 2,136 Other receivables 6,325 (5,907 ) 418 Prepaid expenses and other current assets 44 - 44 Inventory 662 - 662 Property and equipment 4,860 - 4,860 Other long-term assets 2 - 2 Trademark 280 (280 ) - Medicare license 940 (940 ) - Hospital license 13 (1 ) 12 Goodwill 9,447 6,592 16,039 Net assets acquired $ 25,137 $ (900 ) $ 24,237 Net liabilities assumed: Trade accounts payable $ 6,266 $ - $ 6,266 Accrued liabilities 3,198 (708 ) 2,490 Unfavorable lease - 2,740 2,740 Long-term portion of Capital Leases 2,278 168 2,446 Long-term portion of Note Payable 6,052 - 6,052 Total liabilities assumed $ 17,794 $ 2,200 $ 19,994 Consideration: Cash, net of cash acquired $ 1,436 $ - $ 1,436 Debt assumed 5,907 (5,907 ) - Non-controlling interest - 2,807 2,807 Total consideration $ 7,343 $ (3,100 ) $ 4,243 Peak Surgeon Innovations, LLC (“Peak”) In June 2015, the Company acquired Peak, a provider of intraoperative neuromonitoring ("IOM") services for hospitals, surgery centers and other healthcare facilities. The acquisition serves to expand the Company’s service coverage into multiple locations across multiple states. The Company acquired a 100% ownership interest in Peak for cash consideration of $0.9 million and stock consideration of $0.7 million provided to Bryan Hasse (the “Seller”). In addition to such cash and stock consideration, the Seller is eligible to receive a potential earnout payment (in cash or stock at the option of Seller) upon achievement by the IOM service line of certain EBITDA performance metrics. The earnout payment payable to Seller will be an amount equal to three hundred percent of the difference that results from subtracting (a) $0.5 million from (b) the trailing 12 month adjusted EBITDA, measured at November 1, 2016. The earnout payment could range from nil and has no cap. As of December 31, 2015, the Company has recorded an earnout payment liability of $0.1 million. Subsequent to the acquisition date of June 1, 2015, Peak had $1.4 million in revenues and a loss of $0.2 million which is included in the Company’s consolidated statement of earnings for the year ended December 31, 2015. The costs related to the transaction were nominal and were expensed during the year ended December 31, 2015. These costs are included in the corporate general and administrative expenses in the Company’s consolidated statement of earnings for the year ended December 31, 2015. During the measurement period, the Company made the adjustments specified below with a corresponding adjustment to goodwill, and with no material effect on previous-period or current-period earnings. As a result of the acquisition, the Company has recognized $1.0 million of goodwill within our medical services segment which is deductible for tax purposes. The Company believes that the goodwill is primarily comprised of the business opportunities to be realized through Peak’s existing service infrastructure and relationships with health care facilities across the U.S. In addition, the acquisition of Peak allows the Company to vertically integrate its surgical services and capture revenues which have previously been realized by external service providers. The following table summarizes the fair values of the identifiable assets acquired and liabilities assumed at the date of acquisition ( in thousands As Previously Measurement Period Determined Adjustments Revised Net assets acquired: Cash $ 1 $ - $ 1 Trade accounts receivable 315 54 369 Prepaid expenses and other current assets 4 (4 ) - Property and equipment 315 (238 ) 77 Customer relations 500 500 Goodwill 1,318 (344 ) 974 Net assets acquired $ 1,953 $ (32 ) $ 1,921 Net liabilities assumed: Trade accounts payable $ 138 $ - $ 138 Accrued expenes - 107 107 Capital lease liability 315 (238 ) 77 Net liabilities assumed $ 453 $ (131 ) $ 322 Consideration: Cash, net of cash acquired $ 850 $ - $ 850 Stock issued as consideration 650 - 650 Earn out consideration - 99 99 Total consideration $ 1,500 $ 99 $ 1,599 Marsh Lane Surgical Hospital, LLC (“Marsh Lane”) In July 2015, the Company formed Marsh Lane, a Texas limited liability company and wholly owned subsidiary of the Company, and closed the purchase of certain assets (the “Acquisition”) of Victory Medical Center Plano, LP, a Texas limited partnership (“Victory Plano”). The Acquisition was closed following the conclusion of bankruptcy proceedings in the U.S. Bankruptcy Court for the Northern District of Texas, Fort Worth Division, initiated by Victory Plano. The acquisition of Victory Plano serves to establish the Company’s first hospital platform in the Dallas, Texas market for serving a broader patient population with higher acuity. The total purchase price paid by Marsh Lane for the Acquisition was approximately $1.3 million. Subsequent to the acquisition date of July 30, 2015, Marsh Lane had $27.4 million in revenues and income of $9.6 million which is included in the Company’s consolidated statement of earnings for the year ended December 31, 2015. The costs related to the transaction were nominal and were expensed during the year ended December 31, 2015. These costs are included in the corporate general and administrative expenses in the Company’s consolidated statement of earnings for the year ended December 31, 2015. During the measurement period, the Company made the adjustments specified below with a corresponding adjustment to the bargain purchase gain, resulting in a $2.6 million decrease to current period earnings. Fair value of property and equipment was determined based on the cost approach, which considers the replacement cost less economic depreciation. The capital leases assumed consist of medical equipment and contain a bargain purchase option. The following table summarizes the fair values of the identifiable assets acquired and liabilities assumed at the date of acquisition ( in thousands As Previously Measurement Period Determined Adjustments Revised Net assets acquired: Trade accounts receivable $ 3,000 $ (1,500 ) $ 1,500 Medical supplies 881 - 881 Property and equipment 10,170 - 10,170 Hospital license 13 (1 ) 12 Net assets acquired $ 14,064 $ (1,501 ) $ 12,563 Net liabilities assumed: - Capital leases $ 3,907 $ 281 $ 4,188 Debt 4,500 - 4,500 Unfavorable lease liability - 843 843 Total liabilities assumed $ 8,407 $ 1,124 $ 9,531 Consideration: Cash, net of cash acquired $ 1,299 $ - $ 1,299 Bargain purchase gain: $ 4,358 $ (2,625 ) $ 1,733 Scottsdale Liberty Hospital, LLC (“Scottsdale Liberty”) In November 2015, the Company announced the closing of a transaction to jointly own and operate Freedom Pain Hospital (n/k/a Scottsdale Liberty Hospital) located in Scottsdale, Arizona. The Company acquired a 60% interest and management control of the entity which was formed to own and operate the successor hospital. The addition of new facility further complements the operations of our NHSC-S surgical center by expanding our service offerings to a higher acuity patient population. The facility will focus on inpatient bariatric, orthopedic, and neuro-spine procedures. In the transaction, Nobilis contributed approximately $3.2 million to acquire its 60% interest. In addition to managing the corporate affairs of the new hospital, Nobilis will provide day to day management services pursuant to a management agreement executed as part of the transaction. As a result of the acquisition, the Company has preliminarily recognized $6.9 million of goodwill within its medical services segment which is deductible for tax purposes. Subsequent to the acquisition date of July 30, 2015, Scottsdale Liberty had $0.8 million in revenues and a loss of $0.4 million which is included in the Company’s consolidated statement of earnings for the year ended December 31, 2015. The costs related to the transaction were nominal and were expensed during the year ended December 31, 2015. These costs are included in the corporate general and administrative expenses in the Company’s consolidated statement of earnings for the year ended December 31, 2015. The fair value of the noncontrolling interest was determined by: i) grossing up the controlling interest purchase price to an equivalent 100% interest value; ii) applying the non-controlling interest ownership percentage; and iii) applying discounts for lack of control and lack of marketability. The fair values assigned to certain assets acquired and liabilities assumed in relation to the Company’s acquisition have been prepared on a preliminary basis with information currently available and are subject to change. Specifically, the Company is still in the process of assessing the fair value of a capital lease associated with the real property being utilized by the facility, PP&E and the terms of an anti-dilution provision of the agreement to assess if it is a derivative and if a fair value needs to be estimated. The Company expects to finalize its analysis during 2016. The following table summarizes the fair values of the identifiable assets acquired and liabilities assumed at the date of acquisition ( in thousands November 1, 2015 Net assets acquired: Trade accounts receivable $ 82 Prepaid expenses and other current assets 36 Inventory 69 PP&E 13,266 Other long-term assets 113 Goodwill 6,932 Tradename 160 Hospital License 12 Net assets acquired $ 20,670 Net liabilities assumed: Trade accounts payable $ 2,668 Accrued liabilities 419 Current portion of capital leases 1,510 Long-term portion of capital leases 11,361 Total liabilities assumed $ 15,958 Consideration: Cash, net of cash acquired $ 3,180 Non-Controlling Interest 1,532 Total consideration $ 4,712 Unaudited Supplemental Pro Forma Information The following unaudited supplemental pro forma financial information includes the results of operations for First Nobilis, Athas and Scottsdale Liberty, and is presented as if each acquired company had been consolidated as of the beginning of the year immediately preceding the year in which the company was acquired. The Company utilized all historical data which was available and practicable to obtain. Certain information was not practicable to obtain for Hermann Drive and Marsh Lane due to the bankruptcy proceedings of their former parent company. The unaudited supplemental pro forma financial information has been provided for illustrative purposes only and does not purport to be indicative of the actual result that would have been achieved by the combined companies for the periods presented, or of the results that may be achieved by the combined companies in the future. Further, results may vary significantly from the results reflected in the following unaudited supplemental pro forma financial information because of future events and transactions, as well as other factors. Unaudited pro forma information for the Peak acquisition is not presented in the pro forma disclosure because the effects of such transaction is considered immaterial to the Company’s consolidated financial statements. The unaudited supplemental pro forma financial information presented below has been prepared by adjusting the historical results of the Company to include historical results of the acquired businesses described above and was then adjusted: (i) to increase amortization expense resulting from the intangible assets acquired; (ii) to adjust earnings per share to reflect the common shares issued as part of the purchase consideration; (iii) to reduce interest expense from debt which was retained by the seller upon acquisition of the respective businesses; (iv) to adjust the carrying value of net property and equipment to its fair value and to increase depreciation expense for the incremental increase in the value of property and equipment; (v) to decrease expenses for management services which were provided by the preceding parent entity and to concurrently increase expenses for management services which are now provided by the Company; and (vi) to adjust noncontrolling interest to properly reflect the minority ownership percentages which were not purchased by the Company. The unaudited supplemental pro forma financial information does not include adjustments to reflect the impact of other cost savings or synergies that may result from these acquisition. The Company’s unaudited supplemental pro forma financial information is as follows (in thousands except for per share amounts): 2015 2014 Revenue $ 233,581 $ 133,987 Income from operations 24,592 19,399 Net income attributable to noncontrolling interets 10,216 13,593 Net income attributable to common stockholders 46,567 1,326 Net income per basic common share $ 0.69 $ 0.02 |
Investments in Associates
Investments in Associates | 12 Months Ended |
Dec. 31, 2015 | |
Investments in Associates [Text Block] | 5. Investments in Associates In March 2014, the Company acquired an ownership interest in Group of Pioneers Diagnostics (“GOP”), LLC, representing 40% of the outstanding share interests in GOP. The investment in GOP is accounted for using the equity method of accounting. GOP owns two Management Service Organizations (“MSOs”) which provides a suite of management services to their clients which may include, but is not be limited to, general business management, fiscal management and physician practice management. Due to lack of historical and current financial information of GOP and our Company’s separation from the management and operations of GOP, we do not believe there can be any sustainability in the business model. As a result, the investment in GOP was written off in December 2015. The impairment charge of approximately $0.2 million was recorded as other expense in the consolidated statements of earnings. In December 2014, as part of the Athas acquisition, the Company acquired Athas’ investment ownership in two ASC’s and one hospital (the “Athas Investments”): 87.5% in Elite Orthopedic and Spine Surgery Center LLC; 15.7% in Elite Sinus Spine and Ortho LLC; and 10.7% in Elite Hospital Management LLC. For the Athas Investments, the Company concluded that it did not exert significant influence over the operating and financial activities. The Athas Investments are accounted for as cost method investments and recorded at cost. The total carrying value of the Athas Investments at December 31, 2014 was $0.7 million. In December 2015, the Company agreed to divest its interest in the Athas Investments, resulting in a loss of $0.7 million. The impairment charge of $0.7 million was recorded as other expense in the consolidated statements of earnings. During the first quarter of 2015, we completed the deconsolidation of two imaging centers and one urgent care clinic in Houston, which consisted of the following entities: Spring Northwest Management, LLC, Spring Northwest Operating, LLC, Willowbrook Imaging, LLC, GRIP Medical Diagnostics, LLC, and KIRPA Holdings, LLC. We resigned as the manager of these facilities resulting in loss of control and our rights to exercise significant influence. We retained investments in these facilities that are accounted for as cost method investments beginning January 1, 2015. The revaluation of our remaining investments in these facilities resulted in a loss to the Company of $0.8 million. The carrying value as of December 31, 2015 is $0.7 million. The investments are classified as other long-term assets in the consolidated balance sheets. The impairment charge of $0.8 million was recorded as other expense in the consolidated statement of earnings. The fair value of Spring Northwest Management, LLC was determined by the discounted future cash flow method. The fair value of Spring Northwest Operating, LLC (including its two wholly owned subsidiaries, Spring Creek Urgent Care, LLC and Spring Creek Imaging LLC) was determined by the discounted future cash flow method. The fair value of Willowbrook Imaging, LLC and its holding company, GRIP Medical Diagnostics, LLC, was determined based on a liquidation analysis of the underlying assets, using the adjusted net asset value method under the cost approach. The fair value of KIRPA Holdings, LLC was determined based on the adjusted net asset value method under the cost approach. |
Financial Instruments and Conce
Financial Instruments and Concentration | 12 Months Ended |
Dec. 31, 2015 | |
Financial Instruments and Concentration [Text Block] | 6. Financial Instruments and Concentration In common with all other businesses, the Company is exposed to risks that arise from its use of financial instruments. This note describes the Company’s objectives, policies, and processes for managing those risks and the methods used to measure them. Further quantitative information in respect of these risks is presented throughout these consolidated financial statements. Principal financial instruments The principal financial instruments used by the Company, from which financial instrument risk arises, are as follows: • Accounts receivable and other receivables • Investments in associates • Accounts payable, accrued liabilities and other current liabilities • Other liabilities and notes payable • Capital leases • Lines of credit • Debt • Warrants • Non-employee stock options The carrying amounts of the Company’s cash, accounts receivable and other receivables, accounts payable, accrued liabilities, other current liabilities, other liabilities as reflected in the consolidated financial statements approximate fair value due to the short term maturity of these items. The estimated fair value of our other long-term debt instruments approximate their carrying amounts as the interest rates approximate our current borrowing rate for similar debt instruments of comparable maturity, or have variable interest rates. Financial instruments - risk management The Company is exposed through its operations to the following financial risks: • Credit risk • Fair value or cash flow interest rate risk • Foreign exchange risk • Other market price risk • Liquidity risk Credit risk Credit risk is the risk of financial loss to the Company if a patient, non-partner surgeon or insurance company fails to meet its contractual obligations. The Company, in the normal course of business, is exposed mainly to credit risk on its accounts receivable from insurance companies, other third-party payors, and doctors. Accounts receivables are net of applicable bad debt reserves, which are established based on specific credit risk associated with insurance companies and payors and other relevant information. Liquidity risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due and arises from the Company’s management of working capital. The Company’s objective to managing liquidity risk is to ensure that it will have sufficient cash to allow it to meet its liabilities when they become due. To achieve this objective, it seeks to maintain cash balances (or agreed facilities) to meet expected requirements. The liquidity risk of the Company and its subsidiaries is managed centrally by the Company’s finance function. The Company believes that there are currently no concerns of its ability to meet its liabilities as they become due for the foreseeable future. A summary of certain information about our payor concentration is as follows: MEDICAL SERVICES SEGMENT PATIENT AND NET PROFESSIONAL FEEREVENUEBY PAYORS OF THENOBILIS FACILITIES FOR THEYEARS ENDED DECEMBER 31, 2015 AND 2014 2015 Patient and Net 2014 Patient and Net Payors Professional Fee Revenue Professional Fee Revenue by Payor Mix by Payor Mix Private insurance and other private pay 95.5% 97.0% Workers compensation 4.1% 2.3% Medicare 0.4% 0.7% Total 100.0% 100.0% MARKETING SEGMENT PATIENT AND NET PROFESSIONAL FEEREVENUEBY PAYORS OF THENOBILIS FACILITIES FOR THEYEARS ENDED DECEMBER 31, 2015 AND 2014 2015 Patient and Net 2014 Patient and Net Payors Professional Fee Revenue Professional Fee Revenue by Payor Mix by Payor Mix Private insurance and other private pay 100.0% 100.0% Workers compensation 0.0% 0.0% Medicare 0.0% 0.0% Total 100.0% 100.0% Five facilities represent approximately 86% of the Company’s contracted marketing revenue for the year-ended December 31, 2015, and four facilities represent approximately 85% of the Company’s contracted marketing accounts receivable as of December 31, 2015. CONSOLIDATED SEGMENTS PATIENT AND NET PROFESSIONAL FEEREVENUEBY PAYORS OF THENOBILIS FACILITIES FOR THEYEARS ENDED DECEMBER 31, 2015 AND 2014 2015 Patient and Net 2014 Patient and Net Payors Professional Fee Revenue Professional Fee Revenue by Payor Mix by Payor Mix Private insurance and other private pay 95.6% 97.1% Workers compensation 4.0% 2.2% Medicare 0.4% 0.7% Total 100.0% 100.0% Market risk Market risk is the risk that the fair value of future cash flows of financial instruments will fluctuate due to changes in interest rates and/or foreign currency exchange rates. Interest rate risk The Company entered into a revolving line of credit that, from time to time, may increase interest rates based on market index. Foreign exchange risk Foreign exchange risk arises because the Company has certain expenses that are incurred in Canadian dollars. The Company is also exposed to currency risk on purchases made from vendors based in Canada. The Company had Canadian denominated cash (“Cdn”) of $0.3 million and a nominal amount of trade payables at December 31, 2015. The Company had Cdn of $0.1 million and a nominal amount of trade payables at December 31, 2014. |
Trade Accounts Receivable, net
Trade Accounts Receivable, net | 12 Months Ended |
Dec. 31, 2015 | |
Trade Accounts Receivable, net [Text Block] | 7. Trade Accounts Receivable, net A detail of trade accounts receivable, net as of December 31, 2015 and 2014 is as follows ( in thousands) December 31, 2015 December 31, 2014 Trade accounts receivable $ 95,114 $ 40,985 Allowance for doubtful accounts (5,165 ) (1,391 ) Receivables transferred (298 ) (873 ) Receivables purchased 2,918 1,740 Trade accounts receivable, net $ 92,569 $ 40,461 Bad debt expense was $3.6 million and $0 for the year-ended December 31, 2015 and 2014, respectively. From time to time, we transfer to third parties certain of our accounts receivable payments on a non-recourse basis in return for advancement on payment to achieve a faster cash collection. As of December 31, 2015 and 2014, there remained a balance of $0.3 million and $0.9 million, respectively, in transferred receivables pursuant to the terms of the original agreement. For the year-ended December 31, 2015 and 2014, the Company received advanced payments of $1.7 million and $1.0 million, respectively. During the same time period, the Company transferred $7.6 million and $7.3 million of receivables, respectively. Concurrently, upon collection of these transferred receivables, payment will be made to the transferee. Athas Health, LLC (“Athas”) purchases receivables from physicians, at a discount, on a nonrecourse basis. The discount and purchase price vary by specialty and are recorded at the date of purchase, which generally occurs 45 days after the accounts are billed. These purchased receivables are billed and collected by Athas, and Athas retains 100% of what is collected after paying the discounted purchase price. Following the transfer of the receivable, the transferor has no continued involvement and there are no restrictions on the receivables. Gross revenue from purchased receivables was $10.8 million and $1.6 million for the years-ended December 31, 2015 and 2014, respectively. Revenue, net of the discounted purchase price, was $6.2 million and $0.9 million for the years-ended December 31, 2015 and 2014, respectively. Accounts receivable for purchased receivables was $2.0 million and $1.7 million for the years-ended December 31, 2015 and 2014, respectively. Revenue from receivables purchased is recorded in the factoring revenue line item within the consolidated statements of earnings. Peak Surgeon Innovations, LLC (“Peak”) purchases receivables from a third party, at a discount, on a non-recourse basis. The discount and purchase price vary by specialty and are recorded at the date of purchase, which generally occurs 30 days after the accounts are billed. These purchased receivables are billed and collected by Peak, and Peak retains 100% of what is collected after paying the discounted purchase price. Following the transfer of the receivable, the transferor has no continued involvement and there are no restrictions on the receivables. Gross revenue from purchased receivables was $0.5 million for the year -ended December 31, 2015. Revenue, net of the discounted purchase price, was $0.3 million for the year-ended December 31, 2015. Accounts receivable for purchased receivables was $0.6 million for the year-ended December 31, 2015. Comparable prior period amounts are not presented, as Peak was acquired by Nobilis in May 2015. Revenue from receivables purchased is recorded in the factoring revenue line item within the consolidated statements of earnings. Nobilis Surgical Assist, LLC (“First Assist”) purchases receivables from physician’s assistants, at a discount, on a nonrecourse basis. The discount and purchase price vary by specialty and are recorded at the date of purchase, which generally occurs 45 days after the accounts are billed. These purchased receivables are billed and collected by First Assist, and First Assist retains 100% of what is collected after paying the discounted purchase price. Following the transfer of the receivable, the transferor has no continued involvement and there are no restrictions on the receivables. Gross revenue from purchased receivables was $0.2 million for the year-ended December 31, 2015. Revenue, net of the discounted purchase price, was $0.1 million for the year-ended December 31, 2015. Accounts receivable for purchased receivables was $0.2 million for the year-ended December 31, 2015. Comparable prior period amounts are not presented, as First Assist commenced operations under Nobilis in October 2015. Revenue from receivables purchased is recorded in the factoring revenue line item within the consolidated statements of earnings. Factoring Revenues Factoring revenue is comprised of revenue generated from certain accounts receivables which are purchased from third parties through the regular course of business. Purchase price is determined either by a flat fee per case, as dictated per the agreement, or as a percentage of final collections. At the time of purchase, the Company assumes all financial risk and incurs all costs related to collections without any recourse to the third party seller. Net factoring revenue is deferred until such time the receivables are purchased and is subsequently recognized on a straight-lined basis through the date of collection from third-party payors. |
Property and Equipment, net
Property and Equipment, net | 12 Months Ended |
Dec. 31, 2015 | |
Property and Equipment, net [Text Block] | 8. Property and Equipment, net Property and equipment, net consisted of the following as of December 31, 2015 and 2014 (in thousands): 2015 2014 Telephone equipment $ 122 $ 51 Computer hardware 780 510 Computer software 733 569 Furniture and office equipment 1,143 920 Medical equipment 23,482 9,947 Leasehold improvements 7,942 6,290 Building 12,520 - Construction in progress 1,325 - 48,047 18,287 Less: accumulated depreciation (12,744 ) (9,200 ) Property and equipment, net $ 35,303 $ 9,087 Depreciation expense for the years-ended December 31, 2015 and 2014 was $3.7 million and $1.6 million, respectively. |
Intangible Assets
Intangible Assets | 12 Months Ended |
Dec. 31, 2015 | |
Intangible Assets [Text Block] | 9. Intangible Assets Intangible assets at December 31, 2015 and December 31, 2014 consist of the following (in thousands): December 31, 2015 December 31, 2014 Historical Accumulated Accumulated Net Book Accumulated Accumulated Cost Additions Amortization Impairment Value Historical Cost Amortization Impairment Net Book Value Finite Life Non-compete agreements $ 2,761 $ - $ 993 $ - $ 1,768 $ 2,765 $ 857 $ - $ 1,908 Internally developed software 1,980 - 330 - 1,650 1,980 33 - 1,947 Trade secret methodology 5,620 - 468 - 5,152 5,620 47 - 5,573 Physician relationships 2,800 - 130 - 2,670 2,800 47 - 2,753 Customer relationships - 500 24 - 476 - - - - Indefinite Life Tradenames 1,000 160 - - 1,160 1,000 - - 1,000 Trademark 5,610 - - - 5,610 5,610 - - 5,610 Medicare license 8,498 - - 7,401 1,097 8,498 - 7,401 1,097 Hospital license - 36 - - 36 Total $ 28,269 $ 696 $ 1,945 $ 7,401 $ 19,619 $ 28,273 $ 984 $ 7,401 $ 19,888 Amortization expense was $0.9 million and $0.2 for the years ended December 31, 2015 and 2014, respectively. Estimated amortization of intangible assets for the five years and thereafter subsequent to December 31, 2015 is $1.3 million for 2016, 2017, 2018 and 2019, $1.0 million for 2020 and $5.1 million thereafter. The Company assumed real property leases as part of certain acquisitions which required the Company to pay above market rentals through the remainder of the lease terms. The unfavorable lease liability is amortized as a reduction to rent expense over the contractual periods the Company is required to make rental payments under the leases. Estimated amortization of unfavorable leases for the five years and thereafter subsequent to December 31, 2015 is $0.3 million for 2016, 2017, 2018, 2019 and 2020, and $2.1 million thereafter. |
Goodwill
Goodwill | 12 Months Ended |
Dec. 31, 2015 | |
Goodwill [Text Block] | 10. Goodwill The following tables provide information on changes in the carrying amount of goodwill, which is included in the accompanying consolidated balance sheets as of December 31, 2015 and 2014 (in thousands): December 31, 2015 December 31, 2014 Cost $ 183,276 $ 160,032 Accumulated impairment losses (138,443 ) (138,443 ) Total $ 44,833 $ 21,589 Cost December 31, 2015 December 31, 2014 BALANCE - beginning of period $ 160,032 $ 139,671 January 2014 business combination - 701 First Nobilis business combination - 649 Athas business combination - 19,011 Deconsolidation of imaging centers and urgent care clinic (701 ) - Hermann Drive business combination, as adjusted 16,039 - Peak business combination, as adjusted 974 - Scottsdale Liberty business combination 6,932 Total cost $ 183,276 $ 160,032 Accumulated impairment BALANCE - beginning of period $ (138,443 ) $ (138,443 ) Impairment charges during the period - - Total accumulated impairment $ (138,443 ) $ (138,443 ) The Company did not record any impairment charges for the years ended December 31, 2015 or 2014. |
Accrued expenses and other curr
Accrued expenses and other current liabilities | 12 Months Ended |
Dec. 31, 2015 | |
Accrued expenses and other current liabilities [Text Block] | 11. Accrued expenses and other current liabilities The following table presents a summary of items comprising accrued expenses and other current liabilities in the accompanying consolidated balance sheets as of December 31, 2015 and 2014 (in thousands): 2015 2014 Accrued expenses: Accrued salaries and benefits $ 5,309 $ 684 Other 11,339 7,874 Total accrued expenses $ 16,648 $ 8,558 Other current liabilities: Estimated amounts due to third party payors $ 3,795 $ - Other 1,230 1,508 Total other current liabilities $ 5,025 $ 1,508 |
Other long-term liabilities
Other long-term liabilities | 12 Months Ended |
Dec. 31, 2015 | |
Other long-term liabilities [Text Block] | 12. Other long-term liabilities The Company assumed real property leases as part of certain acquisitions which required the Company to pay above market rentals through the remainder of the lease terms. The long-term portion of unfavorable leases included in other-long term liabilities was $3.3 million and $0.3 million for the years ended December 31, 2015 and 2014, respectively. The unfavorable lease liability is amortized as a reduction to rent expense over the contractual periods the Company is required to make rental payments under the leases. Estimated amortization of unfavorable leases for the five years and thereafter subsequent to December 31, 2015 is $0.3 million for 2016, 2017, 2018, 2019 and 2020, and $2.1 million thereafter. |
Lines of Credit
Lines of Credit | 12 Months Ended |
Dec. 31, 2015 | |
Lines of Credit [Text Block] | 13. Lines of Credit On March 31, 2015, the Company secured a $5.0 million revolving line of credit (the “revolver”) from Healthcare Financial Services, LLC (f/k/a General Electric Capital Corporation), or “HFS” maturing in March 2020. The revolver bears interest at a rate of 4% plus LIBOR per annum (effective rate of 4.70% at December 31, 2015) and requires quarterly payments. Principal amounts borrowed under the revolver may be repaid and re-borrowed periodically. The revolver is collateralized by the accounts receivable and physical equipment of all of the Company’s 100% owned subsidiaries as well as the Company’s ownership interest in all less than wholly owned subsidiaries. The Company has $3.0 million outstanding on this revolver as of December 31, 2015. The revolving line of credit is subject to certain restrictive covenants in conjunction with the HFS term loan, as discussed in Note 14. On July 30, 2015, the Company issued a $1.5 million letter of credit to the landlord of the Marsh Lane Surgical Hospital (“Marsh Landlord”) facility in connection with the execution of the hospital facility lease. The Marsh Landlord shall have the right to draw upon the letter of credit in an event of default. The letter of credit is secured by the $5.0 million revolving line of credit from HFS. |
Debt
Debt | 12 Months Ended |
Dec. 31, 2015 | |
Debt [Text Block] | 14. Debt Purchase of Palladium for Surgery Dallas, LLC (“PFSD”) In conjunction with the Company’s purchase of PFSD, the Company entered into a promissory note with the Company’s Chairman for a principal amount of $2.1 million on January 1, 2011. The note was initially amended in March 2012, in conjunction with a private placement of common shares that occurred in January 2012. The note was subsequently amended in March 2013. The amended note had a principal balance of $1.7 million at December 31, 2013 bearing an interest rate at 5.25% per annum until January 2014, when the interest rate increased to 6.25% per annum. The principal amount and any accrued and unpaid interest was due on or before December 31, 2014. Interest payments were payable on a monthly basis. The note was then amended again in December 2014. The amended note has a principal balance of $0.4 million bearing an interest rate at 6.25% per annum. The principal amount and any accrued and unpaid interest is due on or before January 31, 2016. The note was paid off in full in March 2015 using the proceeds from the $20.0 million term loan which the Company secured on March 31, 2015. Term Loan for Athas Athas secured a term loan in 2011 for $0.5 million which was assumed in the acquisition (Note 4). The Company and one of the shareholders are guarantors of the loan. The loan bears interest at 4.0% per annum. The term loan requires monthly payments of principal and interest until the loan matures in May 2016. As of December 31, 2015, there was no balance due on the term loan. The term loan was paid off in full in March 2015 using the proceeds from the $20.0 million term loan which the Company secured on March 31, 2015. Subordinated Notes Payable Athas carries subordinated notes payable which were given as consideration for working capital provided by certain individuals. The subordinated notes interest is payable semi-annually with a principal due at maturity on December 31, 2015. The notes bear interest at a rate of 12.0% per annum and payment is subordinated to all senior secured debt instruments. The outstanding balance of the subordinated notes was $0.6 million at December 31, 2014. Some of the note holders are also employees and shareholders of the Company. As of December 31, 2015, there was no balance due on the subordinated notes payable. The notes payable were paid off in full in March 2015 using the proceeds from the $20.0 million term loan which the Company secured on March 31, 2015. Promissory Note for Spring Northwest Management, LLC (“SNWM”) In November 2013, SNWM, entered into a promissory note with Allegiance Bank Texas. The agreement provided for a $0.9 million loan which matures in November 2018. The note bears interest at a rate of 5.5% per annum and requires monthly payments of principal and interest through November 2018. The promissory note was utilized to finance the purchase of certain medical equipment, all of which serves as collateral against the note. Nobilis is not liable under the above mentioned promissory note. As of December 31, 2015, this promissory note had a $0 balance due to the deconsolidation of SNWM in January 2015. Refer to Note 5. Promissory Note for Willowbrook Imaging, LLC (“WIM”) In January 2014, WIM, a consolidated entity, entered into a promissory note with Branch Bank and Trust Company. The agreement provided for a $0.8 million loan which matures in February 2021. The note bears interest at a fixed rate of 3.65% per annum and requires monthly payments of principal and interest through February 2021. The promissory note was utilized to finance the purchase of certain medical equipment. Nobilis is not liable under the above mentioned promissory note. As of December 31, 2015, this promissory note had a $0 balance due to the deconsolidation of WIM in January 2015. Refer to Note 5. Purchase of Athas In conjunction with the Company’s purchase of Athas, the Company entered into a promissory note with sellers for a principal amount of $12.0 million on December 1, 2014. The sellers represent the 20 previous shareholders of Athas. Payments are to be made to the sellers as follows: (a) $1.0 million payment of principal on December 31, 2014, (b) $1.0 million payment of principal on April 1, 2015, (c) consecutive monthly payments of principal and interest of $0.3 million commencing May 1, 2015 and continuing until April 1, 2018. The note accrued interest at 11% per annum. The seller agreed to defer the principal payment of $1.0 million which was due on December 31, 2014 while the Company secured financing with a commercial lender. As of December 31, 2015, there was no balance due on the promissory note. The promissory note was paid off in full in March 2015 using the proceeds from the $20.0 million term loan which the Company secured on March 31, 2015. 2015 Refinancing On March 31, 2015, the Company secured a $20.0 million term loan from HFS. The term loan bears interest at a rate of 4% plus LIBOR per annum (effective rate of 4.70% at December 31, 2015) and requires quarterly payments of principal and interest until the term loan matures in March 2020. The term loan provides for a 0.70215% LIBOR floor. The term loan is collateralized by the accounts receivable and physical equipment of all of the Company’s 100% owned subsidiaries as well as the Company’s ownership interest in all less than wholly owned subsidiaries. The $20.0 million term loan primarily served to refinance all previously held debt and lines of credit. Debt issuance costs associated with the new credit facility approximated $0.6 million. At December 31, 2015, the outstanding balance is $19.1 million. The credit facility, including both the term loan and revolving line of credit, contains covenants, including a requirement to maintain a fixed charge coverage ratio of at least 2.0 times and a leverage ratio of 2.25 times. As of December 31, 2015, the Company was not in compliance with the covenants of the Loan Agreement related to: prompt joinder of newly created or acquired Subsidiaries of Credit Parties; secured Capital Lease Obligations not to exceed $1,000,000 ; the creation of intercompany debt and failure to pledge such debt to HFS, and the requirement to timely notify HFS of certain commercial tort claims. Upon execution of the Fourth Amendment to Credit Agreement dated as of March 11, 2016 among Northstar Healthcare Acquisitions, L.L.C. and Healthcare Financial Solutions, LLC (as successor in interest to General Electric Capital Corporation) (the “Fourth Amendment”), amending among other things certain of our covenants under the Loan Agreement, and the waiver letter on March 11, 2016, waiving our previous non-compliance as described above, we were in compliance with our covenants under the Loan Agreement. For more information on the Fourth Amendment, please see Note 28. In April 2015, the Company acquired a 55% ownership interest in Victory Medical Center, L.P. for cash and the assumption of certain liabilities and loans. The loan assumed was from UMB Bank n.a., in the amount of $6.1 million. In May 2015, the Company paid off the loan balance with UMB Bank n.a. On July 30, 2015, the Company secured a $4.5 million term loan from LegacyTexas Bank. The term loan bears interest at a rate of 4% plus LIBOR per annum ( 4.425% at December 31, 2015) and requires monthly payments of interest. Monthly payments of principal will commence in August 2016. The term loan matures in July 2020. The term loan is subordinated to the Company’s term loan and revolver with HFS. At December 31, 2015, the outstanding balance is $4.2 million. Commencing in June 2016, the term loan will require the Company to maintain a fixed charge coverage ratio of 1.05 to 1.00 and to maintain its days cash on hand of no less than 30 days. Loan origination fees are deferred and the net amount is amortized over the contractual life of the related loans. Debt at December 31, 2015 consisted of the following (in thousands): December 31, 2015 December 31, 2014 Gross debt $ 26,275 $ 20,074 Less: unamortized loan fees 563 - Debt, net of unamortized loan fees 25,712 20,074 Less: current portion of term loan 1,243 3,437 Less: subordinated notes payable - 635 Less: lines of credit 3,000 5,420 Long-term debt, net of unamortized loan fees $ 21,469 $ 10,582 Future maturities of debt as of December 31, 2015 are as follows (in thousands): Year ending December 31, 2016 $ 1,375 2017 1,900 2018 1,900 2019 1,900 2020 19,200 Total $ 26,275 |
Operating Leases
Operating Leases | 12 Months Ended |
Dec. 31, 2015 | |
Operating Leases [Text Block] | 15. Operating Leases The Company occupies five ASCs, one hospital, one urgent care clinic, one imaging center and two corporate business spaces under operating lease agreements. The Company also leases certain medical equipment. The minimum rental commitments under non-cancellable operating leases, with terms in excess of one year subsequent to December 31, 2015, are as follows (in thousands): Year ending December 31, 2016 $ 10,648 2017 10,132 2018 9,742 2019 9,263 2020 7,361 Thereafter 45,457 Total future commitment 92,603 Less: minimum sublease income to be received (571 ) Total future commitment, net of sublease income $ 92,032 Rent expense was $9.1 million and $3.5 million for the years ended December 31, 2015 and 2014, respectively. |
Capital Leases
Capital Leases | 12 Months Ended |
Dec. 31, 2015 | |
Capital Leases [Text Block] | 16. Capital Leases The Company holds various capital leases for medical equipment which contain bargain purchase options at the end of the lease terms. The remaining minimum capital lease obligations, with terms in excess of one year subsequent to December 31, 2015, are as follows (in thousands): Year ending December 31, 2016 $ 5,193 2017 4,327 2018 2,061 2019 1,820 2020 1,802 Thereafter 9,465 Total minimum rentals 24,668 Less amounts representing interest (5,821 ) Capital lease obligations $ 18,847 Medical equipment with a cost of $7.2 million and $0.7 million were held under capital leases for the years ended December 31, 2015 and 2014, respectively. Capital leases had accumulated depreciation of $1.7 million and $0.1 million for the years ended December 31, 2015 and 2014. |
Fair Value Measurements
Fair Value Measurements | 12 Months Ended |
Dec. 31, 2015 | |
Fair Value Measurements [Text Block] | 17. Fair Value Measurements The Company measures certain financial assets and liabilities at fair value on a recurring basis, including warrant and stock option derivative liabilities. There have been no transfers between fair value measurement levels during the years ended December 31, 2015 and 2014. The following table summarizes our assets and liabilities measured at fair value on a recurring basis as of December 31, 2015 and 2014, aggregated by the level in the fair value hierarchy within which those measurements fall (in thousands): Fair Value Measurements Using Quoted Prices in Active Markets for Identical Assets and Significant Other Significant Liabilities Observable Inputs Unobservable Inputs (Level 1) (Level 2) (Level 3) Total December 31, 2014: Warrant and stock option derivative liabilities $ - $ - $ 6,657 $ 6,657 Total $ - $ - $ 6,657 $ 6,657 December 31, 2015: Warrant and stock option derivative liabilities $ - $ - $ 2,951 $ 2,951 Total $ - $ - $ 2,951 $ 2,951 In certain cases where there is limited activity or less transparency around inputs to valuation, securities are classified as Level 3 within the valuation hierarchy. Level 3 liabilities that were measured at estimated fair value on a recurring basis consist of warrant and stock option derivative liabilities. The estimated fair values of the warrant and stock option derivative liabilities were measured using the Black-Scholes valuation model (refer to Note 20). Due to the nature of valuation inputs, the valuation of the warrants is considered a Level 3 measurement. |
Shareholders Equity
Shareholders Equity | 12 Months Ended |
Dec. 31, 2015 | |
Shareholders Equity [Text Block] | 18. Shareholders’ Equity In total, the Company has issued 73,675,979 and 59,418,227 of its common shares as of December 31, 2015 and 2014, respectively. The Company has unlimited authorized shares. There is no par value assigned to our common shares. In December 2013, the Company issued, through a private placement agreement, 5,862,500 Units, at a price of Cdn$0.80 (USD$0.76) per Unit. Each Unit consists of one common share in the capital of the Company and one-half of one common share purchase warrant exercisable for one additional share at a price of Cdn$1.10 (USD$1.04) . As part of the private placement, the Company also granted 410,375 options to the underwriter at a price of Cdn$0.95 (USD$0.90) . Through the private placement, the Company raised $4.1 million, net of offering costs and commissions of $0.4 million. Of the $4.1 million raised capital, $2.9 million was provided in exchange for stock warrants and other financial instruments, resulting in a remaining $1.2 million which was recorded as an increase to share capital for the year ended December 31, 2013. In August 2014, the Company elected to accelerate the expiry date of the common share purchase warrants originally issued by Nobilis as part of its unit private placement completed on December 16, 2013. Each warrant entitled the holder thereof to purchase one additional common share of Nobilis at a price of Cdn$1.10 (USD$1.04) . Nobilis received total gross proceeds of Cdn$3.2 (USD$2.9) million from the exercise. In September 2014, the Company issued, through a private placement agreement, 5,568,400 Units, at a price of Cdn$1.30 (USD$1.17) per Unit. Each Unit consists of one common share in the capital of the Company and one-half of one common share purchase warrant exercisable for one additional share at a price of Cdn$1.80 (USD$1.62) . As part of the private placement, the Company also granted 389,788 options to the underwriter at a price of Cdn$1.37 (USD$1.23) . Through the private placement, the Company raised $6.1 million, as of September 30, 2014, net of offering costs and commissions of $0.4 million. Of the $6.1 million raised capital, $2.1 million was provided in exchange for stock warrants and other financial instruments, resulting in a remaining $4.0 million which was recorded as an increase to additional paid in capital in the consolidated statement of changes in shareholders’ equity. In December 2014, as part of the consideration given for the acquisition of Athas, the Company issued 6,666,666 shares of Nobilis common stock that are subject to a lock up of up to two years, and the issuance of an additional 4,666,666 shares of Nobilis common stock issued over two years with half issued on the first anniversary of the closing and the second half issued on the second anniversary of the closing. In June 30, 2015, the Company, entered into an agreement with Athas, certain seller parties (the “Athas Sellers”) to the Membership Interest Purchase Agreement dated as of November 26, 2014 (the “MIPA”) and certain other parties. Pursuant to the Agreement, the Athas Sellers agreed to reduce by 836,029 the number of common shares, in the aggregate, that were to be issued on the first and second anniversaries of the MIPA’s closing as contingent purchase price payments (the “Contingent Shares”). In addition, the Agreement accomplished (i) the financing of a $2.7 million debt owed by counterparties to the Agreement, (ii) recoupment of $1.7 million of indemnified expenses, and (iii) indemnification of counterparties with respect to litigation. Also pursuant to the Agreement, the Company accelerated the issuance of the remaining 3,830,638 Contingent Shares, resulting in a $5.7 million adjustment to additional paid in capital. In May 2015, the Company issued, through a private placement agreement, 7,847,668 Units, at a price of Cdn$9.00 (USD$7.46) per Unit. Each Unit is comprised of one treasury unit (a “Treasury Unit”) and one-half of one common share from Donald L. Kramer, Healthcare Ventures, Ltd (a company wholly owned by Dr. Kramer), Harry Fleming or from treasury. Each Treasury Unit is comprised of one-half of one common share of the Company and one-half of one common share purchase warrant exercisable for one additional share at a price of Cdn$11.50 (USD$9.54) . Through the private placement, the Company raised proceeds of $28.4 million, net of offering costs and commissions of $1.9 million. As part of the private placement, the Company also granted 392,383 options to the underwriter at a price of Cdn$9.00 (USD$7.46) . |
Share Based Compensation
Share Based Compensation | 12 Months Ended |
Dec. 31, 2015 | |
Share Based Compensation [Text Block] | 19. Share Based Compensation Restricted Share Unit Plan During 2008, the Board of Directors of the Company (the “BOD”) approved the adoption of a Restricted Share Unit (“RSU”) Plan for employees. Restricted Share Units (“RSUs”) may be granted to employees of Nobilis at the sole discretion of the BOD. Subject to the BOD’s ability to accelerate the vesting of the RSUs if it determines circumstances so warrant, each RSU will generally vest in full on the third anniversary of the date of grant; provided that if there is a change of control of the Company prior to the vesting date of the RSUs and a participant is terminated (or resigns for good reason) within six months following such change of control, a pro rata portion of their unvested RSUs will vest up to the date of the change of control. Upon vesting of his or her RSUs, a participant will be entitled to receive on the vesting date, at the discretion of the BOD either: (a) a lump sum cash payment equal to the number of RSUs multiplied by an average closing price of the common shares on the Toronto Stock Exchange on the redemption date, net of any applicable deductions and withholdings; or (b) that number of common shares equal to the number of RSUs credited to the participant’s RSU account, such common shares to be issued from the Company. The participant is to receive the benefit on, or as soon as practicable after, the vesting date, but in no event later than 90 days after the vesting date. Unlike share options, RSUs do not require the payment of any monetary consideration to the Company. Whenever cash dividends are paid on the Company’s common shares, dividend equivalents in the form of additional RSUs will be credited to each Participant and will become part of his or her award under the RSU Plan. The RSUs representing dividend equivalents will vest and be paid at the same time and in the same manner as the RSUs to which the dividend equivalents pertain. In the event of a Participant’s termination of employment, voluntary or by cause, with the Company prior to any vesting date, the Participant’s rights to any unvested RSUs will be immediately and irrevocably forfeited. If the Participant’s employment with the Company terminates on account of death or disability or is terminated by the Company without cause prior to any vesting date, the Participant will become vested in a prorated portion of his or her unvested RSUs, based on the number of months that have elapsed in the then current vesting period as of the date of termination. The Company recorded compensation expense relative to RSU’s of $5.4 million and $0.3 million for the years ended December 31, 2015 and 2014, respectively. The Company had 2.0 million outstanding RSU’s at December 31, 2015. Share Option Plan In April 2012, the BOD approved the adoption of a Share Option Plan for insiders, employees, and service providers. In May 2012, the Company’s shareholders approved the Share Option Plan, and in July 2012, the Toronto Stock Exchange approved the Share Option Plan. Share options may be granted at the sole discretion of the BOD. The exercise price of an option is determined by the BOD at the time of grant and shall not be less than the current market price. The term of each option is determined by the BOD and shall not exceed 10 years. If an Optionee shall cease to be a Participant for cause, no Option held by such Optionee shall be exercisable following the date on which such Optionee ceases to be a Participant. If an Optionee ceases to be a Participant for any reason other than for cause, any Option held by such Optionee at such time shall remain exercisable in full at any time, and in part from time to time, for a period of 90 days after the date on which the Optionee ceases to be a Participant. If the Participant’s employment with the Company terminates on account of death, any option held by such Participant at the date of death shall be exercisable in whole or in part only by the person or persons to whom the rights of the Participant’s Options pass to by will or laws of descent. The maximum number of RSUs and share options that may be issued under the combined plans is equal to 20.0% of the Company’s issued and outstanding common shares. The Company granted a total of 3,166,782 stock options during the year ended December 31, 2015. Of the options granted during the year ended December 31, 2015, 451,782 of those vest immediately, 450,000 vest ratably over a one year period, 1,865,000 vest ratably over a three year period, and 400,000 cliff vest at the end of a five year period. Under the current share option plan, the Company had approximately 8.3 million options available for future issuance as of December 31, 2015. The following table summarizes stock option activity for the years ended December 31, 2015 and 2014. Weighted- Weighted-Average Shares Underlying Average Exercise Remaining Life Options Price (years) Outstanding at January 1, 2014 700,000 $ 0.39 9.8 Granted 3,068,218 $ 1.47 9.9 Exercised (600,000 ) $ 0.30 Forfeited (50,000 ) $ 1.31 Outstanding at December 31, 2014 3,118,218 $ 1.45 9.8 Exercisable at December 31, 2014 220,000 $ 1.16 9.6 Outstanding at January 1, 2015 3,118,218 $ 1.45 9.8 Granted 3,166,782 $ 4.13 9.5 Exercised (447,787 ) $ 1.13 Forfeited (372,213 ) $ 1.01 Outstanding at December 31, 2015 5,465,000 $ 2.97 9.2 Exercisable at December 31, 2015 2,129,522 $ 2.16 8.8 The table above includes 710,000 options issued to non-employees, 650,000 of which are still outstanding at December 31, 2015. See Note 20 for discussion regarding the accounting and classification of these options in the balance sheet. The total intrinsic value of stock options exercised was $2.1 million and $0.6 million for the years ended December 31, 2015 and 2014, respectively. The total intrinsic value for all in-the-money vested outstanding stock options at December 31, 2015 was $1.8 million. Assuming all stock options outstanding at December 31, 2015 were vested, the total intrinsic value of the in-the-money outstanding stock options would have been $4.1 million. The Company recorded compensation expense relative to employee stock options of $6.1 million and $0.7 million for the years ended December 31, 2015 and 2014, respectively. The fair values of stock options used in recording compensation expense are computed using the Black-Scholes option pricing model. The table below shows the assumptions used in the model for options awarded during the years ended December 31, 2015 and 2014. 2015 2014 Expected price volatility 113% - 122% 120% - 128% Risk free interest rate 1.34% - 1.87% 1.73% - 1.91% Expected annual dividend yield 0% 0% Expected option term (years) 5 - 6 5 - 6 Expected forfeiture rate 1.3% - 5.0% 0% - 8.8% Grant date fair value per share $ 2.53 - $6.10 $ 0.86 - $1.67 Grant date exercise price per share $ 2.97 - $6.31 $ 0.97 - $1.64 For stock options, the Company recognizes share-based compensation net of estimated forfeitures and revises the estimates in the subsequent periods if actual forfeitures differ from the estimates. Forfeiture rates are estimated based on historical experience as well as expected future behavior. |
Warrants and Options Liabilitie
Warrants and Options Liabilities | 12 Months Ended |
Dec. 31, 2015 | |
Warrants and Options Liabilities [Text Block] | 20. Warrants and Options Liabilities Warrants and Options Issued in Private Placements As discussed in Note 18, the Company issued warrants and compensatory options in connection with private placements completed in December 2013, September 2014, and May 2015. These warrants and options have exercise prices denominated in Canadian dollars and as such may not be considered indexed to our stock. Hence, these warrants and options are classified as liabilities under the caption “Warrants and Options Liability” and recorded at estimated fair value at each reporting date, computed using the Black-Scholes valuation method. Changes in the liability from period to period are recorded in the statements of earnings under the caption “Change in fair value of warrant and stock option liabilities”. The estimated fair values of warrants and options accounted for as liabilities were determined on the date of the private placements and at each balance sheet date thereafter using the Black Scholes pricing model with the following inputs: 2015 2014 Risk free interest rate 0.0% - 0.65% 0.13% - 0.67% Expected life in years 0.25 - 2 1 - 2 Expected volatility 71% - 96% 73% - 146% The changes in fair value of the warrants and options liability during the years ended December 31, 2015 and 2014 were as follows (in thousands): 2015 2014 Balance at beginning of year $ 6,657 $ 2,401 Issuance of warrants and options 12,797 2,143 Transferred to equity upon exercise (9,050 ) (1,608 ) Change in fair value recorded in earnings (8,295 ) 3,721 Balance at December 31, 2015 and 2014 $ 2,109 $ 6,657 The following warrants and options were outstanding at December 31, 2015: Number of warrants and Remaining contractual Exercise price in Cnd$ options life (years) 2014 Warrants Cnd$1.80 9 0.75 2014 Options Cnd$1.37 117,810 0.75 2015 Warrants Cnd$11.50 3,923,834 1.40 2015 Options Cnd$9.00 392,383 1.40 Outstanding and exercisable at December 31, 2015 4,434,036 Options Issued to Non-Employees As discussed in Note 19, in 2014 the Company issued options to professionals providing services to the organization. These professionals do not meet the definition of an employee under U.S. GAAP. At December 31, 2015, there were 650,000 options outstanding to these non-employees. Under U.S. GAAP, the value of these option awards is determined at the performance completion date. The Company recognizes expense for the estimated total value of the awards during the period from their issuance until performance completion since the professional services are being rendered during this time. The total expense recognized is adjusted to the final value of the award as determined on the performance completion date. The estimated values of the option awards are determined using the Black Scholes pricing model with the following inputs: 2015 2014 Risk free interest rate 0.26% - 1.85% 0.53% - 2.00% Expected life in years 1 - 6 2 - 6 Expected volatility 74% - 121% 113% - 127% The Company recorded expense for non-employee stock options of $1.7 million and $0.8 million for the year ended December 31, 2015 and 2014, respectively. Options issued to non-employees are reclassified from equity to liabilities on the performance completion date. Under U.S. GAAP, such options may not be considered indexed to our stock because they have exercise prices denominated in Canadian dollars. Hence, these will be classified as liabilities under the caption “Warrant and stock option liabilities” and recorded at estimated fair value at each reporting date, computed using the Black-Scholes valuation method. Changes in the liability from period to period will be recorded in the statements of earnings under the caption “Change in fair value of warrant and stock option liabilities”. At December 31, 2015, there were no unexercised non-employee options requiring liability classification as the performance completion date has not been reached. |
Noncontrolling Interests (Resta
Noncontrolling Interests (Restated) | 12 Months Ended |
Dec. 31, 2015 | |
Noncontrolling Interests (Restated) [Text Block] | 21. Noncontrolling Interests Noncontrolling interests at December 31, 2015 represent an 8.1% interest in The Palladium for Surgery - Houston, Ltd, 75% interest in the Kirby Partnership, 5% interest in MSID, 2.3% interest in MSIH, 60% interest in Houston Procedure Suite, LLC, 50% in NHDM, 60% in NHC ASC - Dallas, 49% in First Nobilis, 40% in FNHM, 45% in Hermann Drive, and 40% in Scottsdale Liberty. Agreements with the third party equity owners in NHC - ASC Dallas and First Nobilis give these owners limited rights to require the Company to repurchase their equity interests upon the occurrence of certain events, none of which were probable of occurring as of December 31, 2015 and 2014. The contingently redeemable noncontrolling interests associated with these entities are classified in the Company’s balance sheet as “temporary” or mezzanine equity. Changes in contingently redeemable noncontrolling interests follow (in thousands): NHC - ASC Dallas First Nobilis Total Balance at January 1, 2014 $ 1,263 $ - $ 1,263 Consolidation of entities upon business combination 5,206 5,206 Distributions (2,846 ) - (2,846 ) Net income attributable to noncontrolling interests 8,237 1,007 9,244 Total contingently redeemable noncontrolling interests at December 31, 2014 $ 6,654 $ 6,213 $ 12,867 Balance at January 1, 2015 6,654 6,213 12,867 Distributions (3,892 ) (7,617 ) (11,509 ) Net income attributable to noncontrolling interests 631 10,236 10,867 Total contingently redeemable noncontrolling interests at December 31, 2015 $ 3,393 $ 8,832 $ 12,225 Certain of our consolidated subsidiaries that are less than wholly owned meet the definition of VIEs, and we hold voting interests in all such entities. We consolidate the activities of VIEs for which we are the primary beneficiary. In order to determine whether we own a variable interest in a VIE, we perform qualitative analysis of the entity’s design, organizational structure, primary decision makers and relevant agreements. Such variable interests include our voting interests, and may also include other interests and rights, including those gained through management contracts. Since our core business is the management and operation of health care facilities, our subsidiaries that are determined to be VIEs represent entities that own, manage and operate such facilities. Voting interests in such entities are typically owned by us, by physicians practicing at these facilities (or entities controlled by them) and other parties associated with the operation of the facilities. In forming such entities, we typically seek to retain operational control and, as a result, in some cases, voting rights we hold are not proportionate to the economic share of our ownership in these entities, which causes them to meet the VIE definition. We consolidate such VIEs if we determine that we are the primary beneficiary because (i) we have the power to direct the activities that most significantly impact the economic performance of the VIE via our rights and obligations associated with the management and operation of the VIE’s health care facilities, and (ii) as a result of our obligation to absorb losses and the right to receive residual returns that could potentially be significant to the VIE, which we have through our equity interests. Our loss exposure typically is limited to our equity investment in these entities. |
Employee Retirement Plan
Employee Retirement Plan | 12 Months Ended |
Dec. 31, 2015 | |
Employee Retirement Plan [Text Block] | 22. Employee Retirement Plan Substantially all of our employees, upon qualification, are eligible to participate in our defined contribution 401(k) plan (the “Plan”). Under the Plan, employees may contribute a portion of their eligible compensation, and the Company matches such contributions annually up to a maximum percentage for participants actively employed, as defined by the Plan documents. Plan expenses were approximately $0.4 million and $0.1 million for the years ended December 31, 2015 and 2014, respectively. Such amounts are reflected in operating salaries and benefits in the accompanying consolidated statements of earnings. |
Earnings per Share (Restated)
Earnings per Share (Restated) | 12 Months Ended |
Dec. 31, 2015 | |
Earnings per Share (Restated) [Text Block] | 23. Earnings per Share Basic net earnings attributable to Nobilis common shareholders, per common share, excludes dilution and is computed by dividing net earnings attributable to Nobilis commons shareholders by the weighted-average number of common shares outstanding during the period. Diluted net earnings attributable to Nobilis common shareholders, per common share, is computed by dividing net earnings attributable to Nobilis common shareholders by the weighted-average number of common shares outstanding during the period plus any potential dilutive common share equivalents, including shares issuable upon the vesting of restricted stock awards, stock option awards and stock warrants as determined under the treasury stock method. For the year ended December 31, 2015, 12.4 million common share equivalents related to restricted stock awards, stock option awards and stock warrants were anti-dilutive and therefore are excluded from the dilutive weighted average number of shares outstanding. A detail of the Company’s EPS is as follows (in thousands except for share and per share amounts): 2015 2014 Basic: Earnings attributable to Nobilis $ 50,840 $ 2,893 Weighted average common shares outstanding 67,015,387 46,517,815 Basic earnings per common share $ 0.76 $ 0.06 Diluted: Earnings attributable to Nobilis $ 50,840 $ 2,893 Weighted average common shares outstanding 67,015,387 46,517,815 Dilutive effect of stock options, warrants, RSU's 8,217,396 1,202,754 Weighted average common shares outstanding assuming dilution 75,232,783 47,720,569 Diluted earnings per common share $ 0.68 $ 0.06 |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2015 | |
Income Taxes [Text Block] | 24. Income Taxes The components of income (benefit) expense for the years-ended December 31, 2015 and 2014 are as follows (in thousands): Deferred Current Total 2015 Federal $ 8,215 $ 509 $ 8,724 States and Local - 1,330 1,330 Foreign - - - Change in deferred tax asset valuation allowance (33,250 ) - (33,250 ) Total $ (25,035 ) $ 1,839 $ (23,196 ) 2014 Federal $ 0 $ - $ 0 States and Local - 480 480 Foreign - - - Change in deferred tax asset valuation allowance 0 - 0 Total $ - $ 480 $ 480 The following table shows the reconciliation between income tax expense reported in our consolidated statement of earnings and comprehensive income and the income tax expense that would have resulted from applying the United States federal income tax rate of 34% to pre-tax income. Though the Company was incorporated in British Columbia, all of the Company’s subsidiaries are incorporated in the United States. Therefore, the Company reconciles the income before income taxes for U.S. tax purposes. 2015 2014 Net income before income tax $ 40,737 $ 16,450 US federal income tax rate 34% 34% Expected U.S. Federal income tax (recovery) 13,851 5,593 Permanent differences / discrete items (1,873 ) 388 State income tax (net of federal benefit) 649 317 Valuation Allowance (33,250 ) (4,566 ) Non-controlling interests (4,106 ) (4,446 ) Others 1,533 3,194 Total income tax (benefit) expense $ (23,196 ) $ 480 The table below sets forth the tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities that are reported in our consolidated balance sheets (in thousands): 2015 2014 Deferred tax assets: Goodwill $ 12,047 $ 15,617 Intangibles 797 1,070 Net operating loss carryforwards - U.S. 5,300 13,814 Interest carry-forward 1,351 1,351 Net operating loss carryforwards - Foreign 7,404 8,153 Allowance for bad debts 1,531 373 Equity compensation 2,479 275 Accrued bonus 1,020 - AMT credit 509 - Valuation allowance (7,403 ) (40,653 ) Net deferred tax assets $ 25,035 $ - There was a partial valuation allowance as of December 31, 2015 and a full valuation allowance as of December 31, 2014, respectively. In assessing the need for a valuation allowance, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based upon the level of historical taxable income, projections for future taxable income over the periods in which the deferred tax assets are deductible, and the scheduled reversal of deferred tax liabilities, management believes a partial and full valuation allowance is necessary at December 31, 2015 and 2014, respectively. The Company reduced the valuation allowance in the fourth quarter of 2015 to reflect the revised assessment of the generation of future taxable income. The revised assessment was based on improved performance of our legacy businesses and the impacts of our 2015 acquisitions. The acquisition of Marsh Lane in July 2015, which commenced operations late in the third quarter of 2015, generated $9.6 million of income from operating until year end. Because these operations (and some of our other acquired operations) were distressed when we purchased them, we could not project future profitable operations until we had some actual operations results as a basis. The Company has Canadian net operating loss carryforwards of approximately $29.6 million which will begin to expire in 2028 and U.S. net operating loss carryforwards of approximately $15.6 million which will begin to expire in 2030. On September 30, 2010 the Company issued 18,778,446 common shares to entities controlled by the Company’s Chairman resulting in a change of ownership greater than 50%. As a result, the U.S. net operating losses are limited by the Internal Revenue Code Section 382. In addition, the Company has approximately $4.0 million in interest carry-forwards that have no expiration date. The Company files income tax returns in the U.S. federal jurisdiction, Canada federal jurisdiction, and several state jurisdictions. Our federal tax returns for 2014, 2013, and 2012 are open for review by taxing authorities. Our Canada and Texas tax returns for 2014, 2013, 2012, and 2011 are open for review by taxing authorities. We are not aware of potential interest, penalties or taxes for federal and Canada income tax returns. The Company had no material uncertain tax positions at December 31, 2015 or 2014. |
Business Segment Information
Business Segment Information | 12 Months Ended |
Dec. 31, 2015 | |
Business Segment Information [Text Block] | 25. Business Segment Information A summary of the business segment information for 2015 and 2014 is as follows (in thousands): Year ended December 31, 2015 Medical Services Marketing Corporate Total Revenues $ 205,730 $ 23,486 $ - $ 229,216 Operating expenses 145,835 19,885 - 165,720 Corporate costs - - 31,846 31,846 Income (loss) from operations 59,895 3,601 (31,846 ) 31,650 Interest expense 351 54 1,192 1,597 Change in fair value of warrant and option liabilities - - (8,985 ) (8,985 ) Bargain purchase (1,733 ) - - (1,733 ) Other income 488 236 (690 ) 34 Income before income taxes $ 60,789 $ 3,311 $ (23,363 ) $ 40,737 Other data: Depreciation and amortization expense $ 3,403 $ 1,128 $ 156 $ 4,687 Income tax expense $ 898 $ 238 $ 703 $ 1,839 Intabgible assets $ 5,462 $ 14,157 $ - $ 19,619 Goodwill $ 25,822 $ 19,011 $ - $ 44,833 Capital expenditures $ 3,653 $ 249 $ 478 $ 4,380 Non-cash acquisition of property and equipment $ 28,373 $ - $ - $ 28,373 Non-cash acquisition of intangibles and goodwill $ 24,641 $ - $ - $ 24,641 Total assets $ 151,324 $ 42,159 $ 48,544 $ 242,027 Total liabilities $ 56,407 $ 3,827 $ 35,716 $ 95,950 The Company’s Marketing Segment started in 2014 following the acquisition of Athas. Prior to the acquisition, the Company operated under one operating segment and therefore, has not presented a prior period comparison of segment information. |
Related Parties
Related Parties | 12 Months Ended |
Dec. 31, 2015 | |
Related Parties [Text Block] | 26. Related Parties In conjunction with the Company’s purchase of PFSD, the Company entered into a promissory note with the Company’s former Chairman, on January 1, 2011. The note was paid off in full in March 2015 using the proceeds from the $20.0 million term loan which the Company secured on March 31, 2015. Refer to Note 14. On June 25, 2013, the Company entered into a promissory note receivable with an executive employee of the Company for a principal amount of $0.2 million. The note bears interest at a rate of 5.5% per annum. The term provides that interest will be calculated at a daily rate and all accrued and unpaid interest shall be paid annually on the first day of July of each successive year. The unpaid principal balance together with all accrued but unpaid interest is due in full on or before June 30, 2017. In 2013, the Company entered into a Management Services Agreement (“MSA”) with Northstar Pain Management P.A. (“NSPM”) NSPM is owned by the Company’s largest shareholder. Operation of NSPM is designed to support the Company’s marketing campaigns. As part of the MSA, the Company provides comprehensive management services to NSPM. At December 31, 2015, the Company was owed approximately $0.7 million from NSPM which was written off. Facility lease costs associated with operating leases of approximately $0.4 million were incurred with affiliated entities during the year ended December 31, 2014. There were no costs associated with these leases during 2015, as these entities were deconsolidated in January 2015. Refer to Note 5 for the deconsolidation. Refer to Note 15 for operating leases. The minority interest holder of First Nobilis, a fully consolidated entity, is also a partial owner of First Street Hospital, L.P. (“First Street Hospital”) and First Street Surgical Center, L.P. (“First Street Surgical”), both of which have an ongoing business relationship with the Company. At December 31, 2015, the Company has a due from these related parties of $0.2 million and due to these related parties of a nominal amount for a net amount owed to the Company of $0.2 million. In addition, the Company leases certain medical equipment from First Street Hospital and First Street Surgical. Equipment lease costs of approximately $2.3 million and $0.6 million were incurred during the years ended December 31, 2015 and 2014, respectively. Certain sellers of Athas are current employees of Athas. The sellers of Athas entered into promissory note with the Company for $12.0 million, as mentioned in a previous footnote. The promissory note was paid off in full in March 2015 using proceeds from the $20 million term loan which the Company secured on March 31, 2015. Refer to Note 14. Certain members of the Company are also members of North American Laserscopic Spine Institute (“NALSI”). In June 2014, NALSI entered into a line of credit agreement with Athas, whereby NALSI may draw up to $0.9 million. The line of credit is subject to 10.00% interest rate and matures on June 9, 2018. There is no outstanding balance as of December 31, 2015. Refer to Note 14. May 2015 Private Placement On May 13, 2015, the Company closed a private placement of 7,847,668 units (the “Units”) at a price of C$9.00 per Unit for aggregate proceeds of C$70.6 million. Each Unit is comprised of one treasury unit (a "Treasury Unit") and one-half of one common share (each whole common share, an "Additional Share") from Donald L. Kramer and Healthcare Ventures, Ltd. (a company controlled by Dr. Kramer) or from Harry Fleming (collectively, the "Selling Shareholders" and the Additional Shares from the Selling Shareholders, the "Secondary Shares") or from treasury (the "Additional Treasury Shares"). Each Treasury Unit is comprised of one-half of one common share of the Company (each whole common share, a “Treasury Unit Share”) and one-half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant”). The Selling Shareholders are affiliates of the Company and received gross proceeds of C$34.4 million. Refer to Note 18. The private placement was approved by the disinterested directors of the Company who concluded that the private placement was entered into on market terms and was fair to the Company. In May 2015, the Company entered into an agreement with one of the Selling Shareholders to reimburse the Company for approximately $0.1 million in legal expenses borne by the Company in connection with the private placement. In December 2015, the Company wrote off this amount. Physician Related Party Transactions Nobilis maintains certain medical directorship, consulting and marketing agreements with various physicians who are also equity owners in Nobilis entities. Material related party arrangements of this nature are described below: • In October 2014 the Company entered into a marketing services agreement with an entity controlled by a physician equity owner. In June 2015, the Company expanded the relationship with this physician equity owner to include consulting, medical directorship and on-call agreements. The Company paid $3.0 million and $0.3 million to Spinal Technologies LLC during the years ended December 31, 2015 and 2014, respectively. During 2015, the Company paid to the physician equity owner $1.2 million in fees owed pursuant to the service agreements. • In July 2014, the Company entered into a marketing services agreement with a physician equity owner and an entity owned by that physician equity owner’s brother. The Company paid 0.6 million and $0.3 million to the marketing services entity during the years ended December 31, 2015 and 2014, respectively. • In September 2013, the Company entered into a book deal with a physician equity owner. In March 2015, the Company entered into a marketing agreement with that physician equity owner and a marketing services company owned by the physician equity owner’s father. The Company paid $3.1 million and $1.0 million to the marketing services entity during the years ended December 31, 2015 and 2014, respectively. |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2015 | |
Commitments and Contingencies [Text Block] | 27. Commitments and Contingencies In the normal course of our business, we are subject to legal proceedings brought by or against us and our subsidiaries. In the opinion of management, the amount of ultimate liability with respect to these actions will not materially impact the financial position, results of operations or liquidity of the Company. Elite Ambulatory Surgery Centers, LLC (“Elite”) filed suit against Athas Health, LLC (“Athas”) and Nobilis Health Corp. in Harris County Texas in early 2015. The lawsuit alleged that our acquisition of Athas caused Athas to violate an exclusive marketing services agreement between itself and Elite, and also caused Athas to violate a non-competition covenant contained in the operating agreements of Elite-affiliate entities in which Athas was an equity owner. As of December 31, 2015 parties to the Elite Litigation are in settlement discussions. The Company currently maintains a reserve of $0.3 million for potential exposure, which we consider adequate. Shareholder Lawsuits After the Company announced it would be restating its 2014 annual financial statements and 2015 first and second quarter interim financial statements, one complaint, Schott v. Nobilis Health Corp. et al, was filed in the United States District Court for the Southern District of Texas against the Company, our former chief executive officer and our current chief financial officer. The complaint seeks class action status on behalf of our shareholders and alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 arising out of the restatement and seeks undisclosed damages. The defendants intend to vigorously defend against these claims and filed a motion to dismiss the consolidated complaint for failure to plead particularized facts supporting a strong inference of scienter on the part of the individual defendants. In response, the Plaintiff filed an amended complaint on March 7, 2016. The deadline to move to seek to be appointed lead plaintiff is March 21, 2016. At this early stage, we are not yet able to determine the likelihood of loss, if any, arising from this matter. In addition, a statement of claim (complaint), Vince Capelli v Nobilis Health Corp. et. al, was filed on January 8, 2016 in the Ontario Superior Court of Justice under court file number CV- 16 - 544173 naming Nobilis Health Corp., certain current and former officers and the Company’s former auditors as defendants. The statement of claim seeks to advance claims on behalf of the plaintiff and on behalf of a class comprised of certain of our shareholders related to, among other things, alleged certain violations of the Ontario Securities Act and seeks damages in the amount of C$80 million plus interest. The defendants intend to vigorously defend against these claims. At this early stage, we are not yet able to determine the likelihood of loss, if any, arising from this matter. |
Subsequent Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2015 | |
Subsequent Events [Text Block] | 28. Subsequent Events On March 11, 2016, the Company entered into the Fourth Amendment (the “Amendment”) to Credit Agreement among Northstar Healthcare Acquisitions, L.L.C. and Healthcare Financial Solutions, LLC (as successor in interest to General Electric Capital Corporation), amending among other things certain of the Company’s covenants under the Loan Agreement. The amended covenants (i) increase the amount of Capital Lease Obligations applicable to the covenants (as such term is defined in the Loan Agreement, as amended) permitted under the Loan Agreement from $1 million to $3 million and (ii) limits the amount of extensions of credit and capital contributions between non wholly owned Credit Parties to $16 million at any time outstanding. For purposes of determining the total amount of credit and capital contributions involving non-wholly owned subsidiary Credit Parties that remain outstanding from time to time, the aggregate amount of capital contributions made in a Credit Party will be reduced by the aggregate amount of distributions or dividends paid by such Credit Party to a Credit Party that is a Wholly-Owned Subsidiary since the date the initial capital contributions were made, and the aggregate amount of credit extensions made to a Credit Party will be reduced by the amount of principal repayments made on such credit extensions. |
Summary of Significant Accoun35
Summary of Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2015 | |
Basis of Presentation [Policy Text Block] | Basis of Presentation The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). |
Principles of Consolidation [Policy Text Block] | Principles of Consolidation The Company consolidates entities in which it has a controlling financial interest. We consolidate subsidiaries in which we hold, directly or indirectly, more than 50% of the voting rights and, in the case of variable interest entities (“VIEs”), with respect to which the Company is determined to be the primary beneficiary. Noncontrolling Interests Variable Interest Entities |
Use of Accounting Estimates [Policy Text Block] | Use of Accounting Estimates The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Estimates most consequential to our consolidated financial statements are in the area of revenue recognition. Because a significant portion of our net patient service revenue is associated with services provided on out-of-network basis, with no contractually agreed-upon reimbursement rates from third-party payors, revenues expected to be realized are estimated based on our historical experience with allowable charges by a given payor for the specific service performed. These estimates are subject to ongoing monitoring and adjustment based on actual experience with final settlements and collections. Other significant estimates include estimates of fair values which management formulates in connection with valuation of assets and liabilities acquired in business combinations and impairment tests of goodwill, intangible assets, property, and certain investments and financial instruments; estimates of useful lives of our property and intangible assets; as well as realizable amounts of accounts receivable and deferred tax assets. |
Revenue Recognition [Policy Text Block] | Revenue Recognition Patient and Net Professional Fees The amounts actually collected by the Company from third-party payors, including private insurers vary among payors, even for identical medical procedures. As such, in estimating net patient service revenues, management evaluates payor mix, (among private health insurance plans, workers’ compensation insurers, government payor plans and patients), historical settlement and payment data for a given payor and type of medical procedure, and current economic conditions and revises its revenue estimates as necessary in subsequent. For services subject to contracted rates with third-party payors, revenues are recognized net of applicable contractual adjustments. Contracted Marketing Revenues Factoring Revenues |
Advertising and Marketing Costs [Policy Text Block] | Advertising and Marketing Costs Advertising costs are expensed as they are incurred. Advertising expense for the years ended December 31, 2015 and 2014 was $35.0 million and $9.9 million, respectively. The Company utilizes many media outlets for marketing to patients which include internet, TV, radio, print, seminar and billboard advertising. Advertising and marketing expense is recorded within both the operating expenses: general and administrative and corporate costs: general and administrative line items within the consolidated statements of earnings. |
Cash [Policy Text Block] | Cash We maintain our cash in bank deposit accounts that at times may exceed federally insured limits. At December 31, 2015 and 2014, our cash deposits exceeded such federally insured limits. We have not experienced any losses in such accounts, and we believe we are not exposed to any significant credit risks on cash. |
Trade Accounts Receivable, net [Policy Text Block] | Trade Accounts Receivable, net Trade accounts receivable, net consists of net patient service revenues and factoring revenues recorded at their net realizable amounts, while contracted marketing revenues are recognized at the fees due from the facilities for marketing services performed pursuant to governing contractual arrangements. On a periodic basis, we evaluate receivables based on the age of the receivable, history of past collections and current credit and economic conditions and adjust the carrying amount accordingly. An account is written off when it is determined that all collection efforts have been exhausted. The Company does not accrue finance or interest charges on accounts receivable. An allowance for uncollectible patient receivables balances, including receivables from non-partner surgeons, is maintained at a level which the Company believes is adequate to absorb probable credit losses. |
Medical Supplies [Policy Text Block] | Medical Supplies Medical supplies consist of various surgical supplies and medications and are carried at the lower of cost or market on the first-in, first-out method. The market value of inventories is determined based on the estimated selling price in the ordinary course of business less the estimated costs of sale, and a reasonable profit margin based on the effort required to sell the inventories. The Company had no write-downs in the carrying amounts of medical supplies inventories for the years ended December 31, 2015 or 2014. |
Property and Equipment [Policy Text Block] | Property and Equipment Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets. Property under capital leases and the related obligation for future lease payments are initially recorded at an amount equal to the lesser of fair value of the property and equipment or the present value of the future lease payments. Leasehold improvements are amortized over the lesser of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense when incurred. We evaluate our long-lived assets for possible impairment annually or whenever events or changes in circumstances indicate that the carrying amount of the asset, or related group of assets, may not be recoverable from estimated future undiscounted cash flows expected to arise from their use and ultimate disposition. If the estimated future undiscounted cash flows are lower than the carrying amount of the assets, we determine the amount of impairment, if any, as the excess of the carrying amount of the long-lived asset over its estimated fair value. The fair value of the assets is estimated based on appraisals, established market values of comparable assets or internal estimates of discounted future net cash flows expected to result from the use and ultimate disposition of the asset. The estimates of these future cash flows are based on assumptions and projections we believe to be reasonable and supportable. They require our subjective judgments and take into account assumptions about revenue and expense growth rates. These assumptions may vary by type of facility and presume stable, improving or, in some cases, declining results at our medical facilities, depending on their specific operating circumstances. We report long-lived assets to be disposed of at the lower of their carrying amounts or fair values less costs to sell. In such circumstances, our estimates of fair value are based on appraisals, established market prices for comparable assets or internal estimates of future net cash flows. Gains and losses on disposals of property and equipment are determined by comparing the proceeds from disposal with the net carrying amount of property and equipment, and are recognized within other expense (income) in the consolidated statement of earnings. |
Goodwill and Intangibles [Policy Text Block] | Goodwill and Intangibles Goodwill represents the excess of the cost of an acquired business over the acquisition-date fair value of the net identifiable assets acquired. Goodwill is reviewed for impairment on an annual basis or more frequently if events or circumstances indicate potential impairment. Such review is performed at the reporting unit level, whereby goodwill balances and identifiable assets and liabilities are assigned to a reporting unit to which they relate. For this purpose, the Company currently has two reporting units which are aligned with its business segments. The Company’s goodwill evaluation for each reporting unit is based on both qualitative and quantitative assessments regarding the fair value of goodwill relative to its carrying amount. The Company assesses qualitative factors to determine if the fair value of its reporting units is more likely than not to exceed its carrying amount, including goodwill. In the event the Company determines that it is more likely than not that a reporting unit’s fair value is lower than its carrying amount, quantitative testing is performed comparing carrying amount of the reporting unit to estimated fair value. Fair value estimates are based on appraisals, established market prices for comparable assets or internal estimates of discounted future net cash flows. If the fair value of the reporting unit exceeds the carrying amount, goodwill is not impaired. If the carrying amount exceeds the fair value, an impairment charge is recognized for the excess of the carrying amount of goodwill over its implied fair value. Indefinite-lived intangible assets consisting of trade names, trademarks, and Medicare and hospital licenses, are not amortizable; however, are evaluated for impairment on an annual basis. Intangible assets subject to amortization, which consist of non-compete agreements, lease contract intangibles, internally developed software, trade secret methodology and physician relationships, are carried at cost less accumulated amortization, which is calculated on a straight-line basis over a period of five to 20 years depending on the asset’s useful life. |
Investments in Unconsolidated Affiliates [Policy Text Block] | Investments in Unconsolidated Affiliates Investments in unconsolidated affiliates include the Company’s investments in non-marketable equity securities that do not represent a controlling financial interest in the investee. Such investment balances are included in the Company’s consolidated balance sheets in Other long-term assets, and include investments accounted for using the equity and the cost method of accounting. Where the Company exercises significant influence over the investee, the Company accounts for its investment under the equity method of accounting. In other cases, the investments in unconsolidated affiliates are accounted for using the cost method of accounting. Whether or not the Company exercises significant influence with respect to an investee depends on an evaluation of several factors including, among others, representation on the investee’s board of directors, ability to participate in setting operating, financial and other policies of the investee, and ownership level. |
Income Taxes [Policy Text Block] | Income Taxes The tax expense for the period comprises current and deferred tax. Tax expense is recognized in the consolidated statement of earnings, except to the extent that it relates to items recognized directly in equity. For items recognized directly in equity, the tax expense is also recognized in equity. The current income tax charge is calculated on the basis of the tax laws enacted at the balance sheet date in the countries where the Company’s subsidiaries operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulations are subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities. Deferred income tax is recognized, using the liability method, on temporary differences arising between the tax base of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred income tax is determined using tax rates (and laws) that have been enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled. Deferred income tax assets are recognized only to the extent that it is probable that future taxable profit against which the temporary difference can be utilized will be available. Deferred income tax is provided on temporary differences arising on investments in subsidiaries and unconsolidated affiliates, except where the timing of the reversal of the temporary difference is controlled by the Company and it is probable that the temporary difference will not reverse in the foreseeable future. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. The Company annually evaluates tax positions to determine the need for any additional disclosures, de-recognition, classification, interest and penalties on income taxes and accounting for income tax estimates in interim periods. In assessing the need for a valuation allowance, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. |
Fair value [Policy Text Block] | Fair Value Certain financial instruments are reported at fair value on our consolidated balance sheets. Under fair value measurement accounting guidance, fair value is defined as the amount that would be received from the sale of an asset or paid for the transfer of a liability in an orderly transaction between market participants, (i.e., an exit price). To estimate an exit price, a three-level hierarchy is used. The fair value hierarchy prioritizes the inputs, which refer broadly to assumptions market participants would use in pricing an asset or a liability, into three levels. Level 1 inputs are unadjusted quoted prices in active markets for identical assets and liabilities and have the highest priority. Level 2 inputs are inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly (such as quoted prices for similar assets or liabilities). Level 3 inputs are unobservable inputs for the asset or liability and have the lowest priority (such as cash-flow assumptions formulated by management). |
Leases [Policy Text Block] | Leases Certain leases to which the Company is party as a lessee are classified as capital leases whenever the terms of the lease transfer to the Company substantially all of the risks and rewards of ownership. Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases (net of any incentives received from the lessor) are charged to the consolidated statement of earnings on a straight-line basis over the period of the lease as rent expense. |
Foreign Currency [Policy Text Block] | Foreign Currency The Company has no significant business operations outside the United States and, therefore, the functional currency and the local currency for its business operations is the U.S. Dollar (“USD”). The accompanying consolidated statements are also presented in USD, the Company’s reporting currency. From time to time monetary assets and liabilities may be denominated in foreign currency, and, if so, will be translated at the exchange rate in effect as of the balance sheet date, with resulting gains or losses included within the consolidated statement of earnings. Revenues and expenses denominated in foreign currencies are translated into USD at the average foreign currency exchange rate for the period. |
Stock-Based Compensation [Policy Text Block] | Stock-Based Compensation The Company recognizes all stock-based compensation to employees, including grants of employee stock options, in the consolidated financial statements based on their grant-date fair values. The Company values its stock options awarded using the Black-Scholes option pricing model. Restricted stock awards are valued at the grant-date closing market price. Stock-based compensation costs are recognized over the vesting period, which is the period during which the employee is required to provide service in exchange for the award. Occasionally, the Company issues stock-based awards to non-employees. The fair value of these option awards is estimated when the award recipient completes the contracted professional services. The Company recognizes expense for the estimated total value of the awards during the period from their issuance until performance completion, at which time the estimated expense is adjusted to the final value of the award as measured at performance completion. Because our non-employee stock options were issued with exercise prices denominated in Canadian Dollars, upon performance completion, their fair values are reclassified from equity to liabilities and remeasured to fair value each reporting period, with remeasurement gains and losses recognized in other income (expense) in our consolidated statements of earnings. |
Net Income Per Common Share [Policy Text Block] | Net Income per Common Share We calculate net income per common share by dividing net income available for common shareholders by the weighted average number of common shares outstanding during the period. Fully diluted income per share is computed using the weighted average number of common and potential common shares outstanding during the period. Potential common shares include those that may be issued upon redemption of units granted under the Company’s restricted stock unit and Share Option Plans. |
Segment Reporting [Policy Text Block] | Segment Reporting The Company reports segment information based on how the chief operating decision maker, along with other members of management, organize and utilize financial and operational data in determining how to allocate resources and assess performance. |
Reclassifications [Policy Text Block] | Reclassifications and Corrections Certain amounts in the consolidated financial statements and these notes have been reclassified to conform to the current period presentation. Additionally, corrections were made to the 2014 financial statements to correct the presentation of foreign currency translation amounts to foreign currency transaction amounts and correct the presentation of the 2014 deferred tax inventory in Note 24. The reclassifications included in these comparative consolidated financial statements are (i) a reclassification of an unfavorable lease liability from intangible assets to other long-term liabilities, (ii) a balance sheet reclassification between property and equipment and accumulated depreciation of property and equipment. The reclassifications and corrections were deemed to be immaterial to the consolidated financial statements both individually and in the aggregate. The correction of other comprehensive income resulted in a decrease in 2014 net income of $0.2 million and a decrease in both basic and diluted earnings per share of $0.01. The correction of the deferred tax inventory had no impact on net income because of the full valuation allowance at December 31, 2014. |
Recent Accounting Pronouncements [Policy Text Block] | Recent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09 “Revenue from Contracts with Customers” that provides a single, comprehensive revenue recognition model for all contracts with customers and supersedes current revenue recognition guidance. The revenue standard contains principles that an entity will apply to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity will recognize revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange for those goods or services. On July 9, 2015, the FASB voted to approve a one-year deferral of the effective date. This new guidance is now effective for annual reporting periods beginning after December 15, 2017. The standard allows for either “full retrospective” adoption, meaning the standard is applied to all of the periods presented, or “modified retrospective” adoption, meaning the standard is applied only to the most current period presented in the financial statements, with the cumulative effect of initial disclosure of the effect of using this method of adoption on the financial statement line items. The Company is currently evaluating the new guidance to determine the method of adoption that it will use and the impact it will have on its consolidated financial statements. In June 2014, the FASB issued ASU No. 2014-12 “Compensation – Stock Compensation” that provides amended guidance on the accounting for certain share-based employee compensation awards. The amended guidance applies to share-based employee compensation awards that include a performance target that affects vesting when the performance target can be achieved after the requisite service period. These targets are to be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award and compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved. The amendments are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. The Company does not expect adoption will have a material impact on its consolidated financial statements. In February 2015, the FASB issued ASU No. 2015-02 “Consolidation (Topic 810): Amendments to the Consolidation Analysis” that amends the current consolidation guidance. The amendments affect both the variable interest entity and voting interest entity consolidation models. The guidance must be applied using one of two retrospective application methods and will be effective for fiscal years beginning after December 15, 2015, and for interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The Company does not expect adoption will have a material impact on its consolidated financial statements. In April 2015, the FASB issued ASU No. 2015-03 “Simplifying the Presentation of Debt Issuance Costs,” which requires that debt issuance costs be presented in the balance sheet as a direct deduction from the carrying amount of related debt liability, consistent with debt discounts. Under the former accounting standards, such costs were recorded as an asset. On August 18, 2015, the FASB clarified that the guidance in ASU No. 2015-03 does not apply to line-of-credit arrangements. Accordingly, companies may continue to present debt issuance costs for line-of-credit arrangements as an asset and subsequently amortize the deferred debt costs ratably over the term of the arrangement. This new guidance is effective for annual reporting periods beginning after December 15, 2015. The Company adopted this ASU in the second quarter of 2015. |
Supplemental Cash Flow Inform36
Supplemental Cash Flow Information (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] | 2015 2014 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid for interest $ 1,236 $ 165 Cash paid for taxes $ 427 $ 216 SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Non-cash acquisition of property and equipment $ 28,373 $ 2,271 Non-cash acquisition of goodwill and intagibles $ 24,641 $ 7,206 Non-cash deconsolidation of property and equipment $ 2,828 $ - Non-cash deconsolidation of goodwill $ 701 $ - Non-cash purchase of medical equipment through capital lease $ - $ 696 Stock consideration given for purchase of interest in subsidiary $ 650 $ - Athas settlement in lieu of contingent shares $ 5,685 $ - |
Acquisitions and Business Com37
Acquisitions and Business Combinations (Tables) | 1 Months Ended | 12 Months Ended | ||||||
Nov. 30, 2015 | Jul. 31, 2015 | Jun. 30, 2015 | Apr. 30, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jan. 31, 2014 | Dec. 31, 2015 | |
Schedule of Fair Value of Identifiable Assets [Table Text Block] | November 1, 2015 Net assets acquired: Trade accounts receivable $ 82 Prepaid expenses and other current assets 36 Inventory 69 PP&E 13,266 Other long-term assets 113 Goodwill 6,932 Tradename 160 Hospital License 12 Net assets acquired $ 20,670 Net liabilities assumed: Trade accounts payable $ 2,668 Accrued liabilities 419 Current portion of capital leases 1,510 Long-term portion of capital leases 11,361 Total liabilities assumed $ 15,958 Consideration: Cash, net of cash acquired $ 3,180 Non-Controlling Interest 1,532 Total consideration $ 4,712 | As Previously Measurement Period Determined Adjustments Revised Net assets acquired: Trade accounts receivable $ 3,000 $ (1,500 ) $ 1,500 Medical supplies 881 - 881 Property and equipment 10,170 - 10,170 Hospital license 13 (1 ) 12 Net assets acquired $ 14,064 $ (1,501 ) $ 12,563 Net liabilities assumed: - Capital leases $ 3,907 $ 281 $ 4,188 Debt 4,500 - 4,500 Unfavorable lease liability - 843 843 Total liabilities assumed $ 8,407 $ 1,124 $ 9,531 Consideration: Cash, net of cash acquired $ 1,299 $ - $ 1,299 Bargain purchase gain: $ 4,358 $ (2,625 ) $ 1,733 | As Previously Measurement Period Determined Adjustments Revised Net assets acquired: Cash $ 1 $ - $ 1 Trade accounts receivable 315 54 369 Prepaid expenses and other current assets 4 (4 ) - Property and equipment 315 (238 ) 77 Customer relations 500 500 Goodwill 1,318 (344 ) 974 Net assets acquired $ 1,953 $ (32 ) $ 1,921 Net liabilities assumed: Trade accounts payable $ 138 $ - $ 138 Accrued expenes - 107 107 Capital lease liability 315 (238 ) 77 Net liabilities assumed $ 453 $ (131 ) $ 322 Consideration: Cash, net of cash acquired $ 850 $ - $ 850 Stock issued as consideration 650 - 650 Earn out consideration - 99 99 Total consideration $ 1,500 $ 99 $ 1,599 | As Previously Measurement Period Determined Adjustments Revised Net assets acquired: Cash $ 64 $ - $ 64 Trade accounts receivable 2,500 (364 ) 2,136 Other receivables 6,325 (5,907 ) 418 Prepaid expenses and other current assets 44 - 44 Inventory 662 - 662 Property and equipment 4,860 - 4,860 Other long-term assets 2 - 2 Trademark 280 (280 ) - Medicare license 940 (940 ) - Hospital license 13 (1 ) 12 Goodwill 9,447 6,592 16,039 Net assets acquired $ 25,137 $ (900 ) $ 24,237 Net liabilities assumed: Trade accounts payable $ 6,266 $ - $ 6,266 Accrued liabilities 3,198 (708 ) 2,490 Unfavorable lease - 2,740 2,740 Long-term portion of Capital Leases 2,278 168 2,446 Long-term portion of Note Payable 6,052 - 6,052 Total liabilities assumed $ 17,794 $ 2,200 $ 19,994 Consideration: Cash, net of cash acquired $ 1,436 $ - $ 1,436 Debt assumed 5,907 (5,907 ) - Non-controlling interest - 2,807 2,807 Total consideration $ 7,343 $ (3,100 ) $ 4,243 | December 2014 Net assets acquired: Cash $ (53 ) Trade accounts receivable 4,713 Other receivable 450 Prepaid expenses 226 Investment in associate 730 PP&E 752 Trademark 5,610 Internally developed software 1,980 Non-compete agreements 1,920 Trade secret medical technology 5,620 Goodwill 19,011 Net assets acquired $ 40,959 Net liabilities assumed: Trade accounts payable $ 1,531 Accrued liabilities 2,915 Line of credit 4,120 Subordinated notes payable 635 Note payable 157 Other current liabilities 102 Other long-term liabilities 260 Total liabilities assumed $ 9,720 Consideration: Cash, net of cash acquired $ 3,000 Debt issued for consideration 12,000 Stock issued for consideration 16,239 Total consideration $ 31,239 | September 2014 Net assets acquired: Accounts receivable $ 6,509 Inventory 598 Trade name 1,000 Physician relationships 2,800 Goodwill 649 Net assets acquired $ 11,556 Net liabilities assumed: Accounts payable $ 6,060 Unfavorable lease 290 Total liabilities assumed $ 6,350 Consideration: 49% ownership interest $ 5,206 | January 16, 2014 Net assets acquired: Cash $ 563 Prepaid expenses 48 Property and equipment 2,271 Other assets 40 Goodwill 701 Net assets acquired $ 3,623 Net liabilities assumed: Accounts payable $ 697 Debt 1,544 Net liabilities assumed $ 2,241 Consideration: Cash, net of cash acquired $ 346 Stock issued for acquisition 514 Noncontrolling interest 522 Total Consideration $ 1,382 | |
Business Acquisition, Pro Forma Information [Table Text Block] | 2015 2014 Revenue $ 233,581 $ 133,987 Income from operations 24,592 19,399 Net income attributable to noncontrolling interets 10,216 13,593 Net income attributable to common stockholders 46,567 1,326 Net income per basic common share $ 0.69 $ 0.02 |
Financial Instruments and Con38
Financial Instruments and Concentration (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] | 2015 Patient and Net 2014 Patient and Net Payors Professional Fee Revenue Professional Fee Revenue by Payor Mix by Payor Mix Private insurance and other private pay 95.6% 97.1% Workers compensation 4.0% 2.2% Medicare 0.4% 0.7% Total 100.0% 100.0% |
Medical services [Member] | |
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] | 2015 Patient and Net 2014 Patient and Net Payors Professional Fee Revenue Professional Fee Revenue by Payor Mix by Payor Mix Private insurance and other private pay 95.5% 97.0% Workers compensation 4.1% 2.3% Medicare 0.4% 0.7% Total 100.0% 100.0% |
Marketing & Factoring [Member] | |
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block] | 2015 Patient and Net 2014 Patient and Net Payors Professional Fee Revenue Professional Fee Revenue by Payor Mix by Payor Mix Private insurance and other private pay 100.0% 100.0% Workers compensation 0.0% 0.0% Medicare 0.0% 0.0% Total 100.0% 100.0% |
Trade Accounts Receivable, net
Trade Accounts Receivable, net (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] | December 31, 2015 December 31, 2014 Trade accounts receivable $ 95,114 $ 40,985 Allowance for doubtful accounts (5,165 ) (1,391 ) Receivables transferred (298 ) (873 ) Receivables purchased 2,918 1,740 Trade accounts receivable, net $ 92,569 $ 40,461 |
Property and Equipment, net (Ta
Property and Equipment, net (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Schedule of Property, Plant and Equipment [Table Text Block] | 2015 2014 Telephone equipment $ 122 $ 51 Computer hardware 780 510 Computer software 733 569 Furniture and office equipment 1,143 920 Medical equipment 23,482 9,947 Leasehold improvements 7,942 6,290 Building 12,520 - Construction in progress 1,325 - 48,047 18,287 Less: accumulated depreciation (12,744 ) (9,200 ) Property and equipment, net $ 35,303 $ 9,087 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Schedule of Finite-Lived Intangible Assets [Table Text Block] | December 31, 2015 December 31, 2014 Historical Accumulated Accumulated Net Book Accumulated Accumulated Cost Additions Amortization Impairment Value Historical Cost Amortization Impairment Net Book Value Finite Life Non-compete agreements $ 2,761 $ - $ 993 $ - $ 1,768 $ 2,765 $ 857 $ - $ 1,908 Internally developed software 1,980 - 330 - 1,650 1,980 33 - 1,947 Trade secret methodology 5,620 - 468 - 5,152 5,620 47 - 5,573 Physician relationships 2,800 - 130 - 2,670 2,800 47 - 2,753 Customer relationships - 500 24 - 476 - - - - Indefinite Life Tradenames 1,000 160 - - 1,160 1,000 - - 1,000 Trademark 5,610 - - - 5,610 5,610 - - 5,610 Medicare license 8,498 - - 7,401 1,097 8,498 - 7,401 1,097 Hospital license - 36 - - 36 Total $ 28,269 $ 696 $ 1,945 $ 7,401 $ 19,619 $ 28,273 $ 984 $ 7,401 $ 19,888 |
Goodwill (Tables)
Goodwill (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Goodwill Cost and Impairment Losses [Table Text Block] | December 31, 2015 December 31, 2014 Cost $ 183,276 $ 160,032 Accumulated impairment losses (138,443 ) (138,443 ) Total $ 44,833 $ 21,589 |
Schedule of Goodwill [Table Text Block] | Cost December 31, 2015 December 31, 2014 BALANCE - beginning of period $ 160,032 $ 139,671 January 2014 business combination - 701 First Nobilis business combination - 649 Athas business combination - 19,011 Deconsolidation of imaging centers and urgent care clinic (701 ) - Hermann Drive business combination, as adjusted 16,039 - Peak business combination, as adjusted 974 - Scottsdale Liberty business combination 6,932 Total cost $ 183,276 $ 160,032 Accumulated impairment BALANCE - beginning of period $ (138,443 ) $ (138,443 ) Impairment charges during the period - - Total accumulated impairment $ (138,443 ) $ (138,443 ) |
Accrued expenses and other cu43
Accrued expenses and other current liabilities (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] | 2015 2014 Accrued expenses: Accrued salaries and benefits $ 5,309 $ 684 Other 11,339 7,874 Total accrued expenses $ 16,648 $ 8,558 Other current liabilities: Estimated amounts due to third party payors $ 3,795 $ - Other 1,230 1,508 Total other current liabilities $ 5,025 $ 1,508 |
Debt (Tables)
Debt (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Schedule of Long-term Debt Instruments [Table Text Block] | December 31, 2015 December 31, 2014 Gross debt $ 26,275 $ 20,074 Less: unamortized loan fees 563 - Debt, net of unamortized loan fees 25,712 20,074 Less: current portion of term loan 1,243 3,437 Less: subordinated notes payable - 635 Less: lines of credit 3,000 5,420 Long-term debt, net of unamortized loan fees $ 21,469 $ 10,582 |
Schedule of Maturities of Long-term Debt [Table Text Block] | Year ending December 31, 2016 $ 1,375 2017 1,900 2018 1,900 2019 1,900 2020 19,200 Total $ 26,275 |
Operating Leases (Tables)
Operating Leases (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] | Year ending December 31, 2016 $ 10,648 2017 10,132 2018 9,742 2019 9,263 2020 7,361 Thereafter 45,457 Total future commitment 92,603 Less: minimum sublease income to be received (571 ) Total future commitment, net of sublease income $ 92,032 |
Capital Leases (Tables)
Capital Leases (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block] | Year ending December 31, 2016 $ 5,193 2017 4,327 2018 2,061 2019 1,820 2020 1,802 Thereafter 9,465 Total minimum rentals 24,668 Less amounts representing interest (5,821 ) Capital lease obligations $ 18,847 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Schedule of Fair Value, by Balance Sheet Grouping [Table Text Block] | Fair Value Measurements Using Quoted Prices in Active Markets for Identical Assets and Significant Other Significant Liabilities Observable Inputs Unobservable Inputs (Level 1) (Level 2) (Level 3) Total December 31, 2014: Warrant and stock option derivative liabilities $ - $ - $ 6,657 $ 6,657 Total $ - $ - $ 6,657 $ 6,657 December 31, 2015: Warrant and stock option derivative liabilities $ - $ - $ 2,951 $ 2,951 Total $ - $ - $ 2,951 $ 2,951 |
Share Based Compensation (Table
Share Based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | Weighted- Weighted-Average Shares Underlying Average Exercise Remaining Life Options Price (years) Outstanding at January 1, 2014 700,000 $ 0.39 9.8 Granted 3,068,218 $ 1.47 9.9 Exercised (600,000 ) $ 0.30 Forfeited (50,000 ) $ 1.31 Outstanding at December 31, 2014 3,118,218 $ 1.45 9.8 Exercisable at December 31, 2014 220,000 $ 1.16 9.6 Outstanding at January 1, 2015 3,118,218 $ 1.45 9.8 Granted 3,166,782 $ 4.13 9.5 Exercised (447,787 ) $ 1.13 Forfeited (372,213 ) $ 1.01 Outstanding at December 31, 2015 5,465,000 $ 2.97 9.2 Exercisable at December 31, 2015 2,129,522 $ 2.16 8.8 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | 2015 2014 Expected price volatility 113% - 122% 120% - 128% Risk free interest rate 1.34% - 1.87% 1.73% - 1.91% Expected annual dividend yield 0% 0% Expected option term (years) 5 - 6 5 - 6 Expected forfeiture rate 1.3% - 5.0% 0% - 8.8% Grant date fair value per share $ 2.53 - $6.10 $ 0.86 - $1.67 Grant date exercise price per share $ 2.97 - $6.31 $ 0.97 - $1.64 |
Warrants and Options Liabilit49
Warrants and Options Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Schedule of Stockholders' Equity Note, Warrants or Rights, Valuation Assumptions [Table Text Block] | 2015 2014 Risk free interest rate 0.0% - 0.65% 0.13% - 0.67% Expected life in years 0.25 - 2 1 - 2 Expected volatility 71% - 96% 73% - 146% |
Schedule of Stockholders' Equity Note, Warrants or Rights, Activity [Table Text Block] | 2015 2014 Balance at beginning of year $ 6,657 $ 2,401 Issuance of warrants and options 12,797 2,143 Transferred to equity upon exercise (9,050 ) (1,608 ) Change in fair value recorded in earnings (8,295 ) 3,721 Balance at December 31, 2015 and 2014 $ 2,109 $ 6,657 |
Schedule of Disclosure of Share-based Compensation Arrangements by Share-based Payment Award and Warrants or Rights[Table Text Block] | Number of warrants and Remaining contractual Exercise price in Cnd$ options life (years) 2014 Warrants Cnd$1.80 9 0.75 2014 Options Cnd$1.37 117,810 0.75 2015 Warrants Cnd$11.50 3,923,834 1.40 2015 Options Cnd$9.00 392,383 1.40 Outstanding and exercisable at December 31, 2015 4,434,036 |
Schedule of Stockholders' Equity Note, Option Awards, Valuation Assumptions [Table Text Block] | 2015 2014 Risk free interest rate 0.26% - 1.85% 0.53% - 2.00% Expected life in years 1 - 6 2 - 6 Expected volatility 74% - 121% 113% - 127% |
Noncontrolling Interests (Res50
Noncontrolling Interests (Restated) (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Redeemable Noncontrolling Interest [Table Text Block] | NHC - ASC Dallas First Nobilis Total Balance at January 1, 2014 $ 1,263 $ - $ 1,263 Consolidation of entities upon business combination 5,206 5,206 Distributions (2,846 ) - (2,846 ) Net income attributable to noncontrolling interests 8,237 1,007 9,244 Total contingently redeemable noncontrolling interests at December 31, 2014 $ 6,654 $ 6,213 $ 12,867 Balance at January 1, 2015 6,654 6,213 12,867 Distributions (3,892 ) (7,617 ) (11,509 ) Net income attributable to noncontrolling interests 631 10,236 10,867 Total contingently redeemable noncontrolling interests at December 31, 2015 $ 3,393 $ 8,832 $ 12,225 |
Earnings per Share (Restated) (
Earnings per Share (Restated) (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | 2015 2014 Basic: Earnings attributable to Nobilis $ 50,840 $ 2,893 Weighted average common shares outstanding 67,015,387 46,517,815 Basic earnings per common share $ 0.76 $ 0.06 Diluted: Earnings attributable to Nobilis $ 50,840 $ 2,893 Weighted average common shares outstanding 67,015,387 46,517,815 Dilutive effect of stock options, warrants, RSU's 8,217,396 1,202,754 Weighted average common shares outstanding assuming dilution 75,232,783 47,720,569 Diluted earnings per common share $ 0.68 $ 0.06 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | Deferred Current Total 2015 Federal $ 8,215 $ 509 $ 8,724 States and Local - 1,330 1,330 Foreign - - - Change in deferred tax asset valuation allowance (33,250 ) - (33,250 ) Total $ (25,035 ) $ 1,839 $ (23,196 ) 2014 Federal $ 0 $ - $ 0 States and Local - 480 480 Foreign - - - Change in deferred tax asset valuation allowance 0 - 0 Total $ - $ 480 $ 480 |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | 2015 2014 Net income before income tax $ 40,737 $ 16,450 US federal income tax rate 34% 34% Expected U.S. Federal income tax (recovery) 13,851 5,593 Permanent differences / discrete items (1,873 ) 388 State income tax (net of federal benefit) 649 317 Valuation Allowance (33,250 ) (4,566 ) Non-controlling interests (4,106 ) (4,446 ) Others 1,533 3,194 Total income tax (benefit) expense $ (23,196 ) $ 480 |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | 2015 2014 Deferred tax assets: Goodwill $ 12,047 $ 15,617 Intangibles 797 1,070 Net operating loss carryforwards - U.S. 5,300 13,814 Interest carry-forward 1,351 1,351 Net operating loss carryforwards - Foreign 7,404 8,153 Allowance for bad debts 1,531 373 Equity compensation 2,479 275 Accrued bonus 1,020 - AMT credit 509 - Valuation allowance (7,403 ) (40,653 ) Net deferred tax assets $ 25,035 $ - |
Business Segment Information (T
Business Segment Information (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Schedule of Segment Reporting Information, by Segment [Table Text Block] | Year ended December 31, 2015 Medical Services Marketing Corporate Total Revenues $ 205,730 $ 23,486 $ - $ 229,216 Operating expenses 145,835 19,885 - 165,720 Corporate costs - - 31,846 31,846 Income (loss) from operations 59,895 3,601 (31,846 ) 31,650 Interest expense 351 54 1,192 1,597 Change in fair value of warrant and option liabilities - - (8,985 ) (8,985 ) Bargain purchase (1,733 ) - - (1,733 ) Other income 488 236 (690 ) 34 Income before income taxes $ 60,789 $ 3,311 $ (23,363 ) $ 40,737 Other data: Depreciation and amortization expense $ 3,403 $ 1,128 $ 156 $ 4,687 Income tax expense $ 898 $ 238 $ 703 $ 1,839 Intabgible assets $ 5,462 $ 14,157 $ - $ 19,619 Goodwill $ 25,822 $ 19,011 $ - $ 44,833 Capital expenditures $ 3,653 $ 249 $ 478 $ 4,380 Non-cash acquisition of property and equipment $ 28,373 $ - $ - $ 28,373 Non-cash acquisition of intangibles and goodwill $ 24,641 $ - $ - $ 24,641 Total assets $ 151,324 $ 42,159 $ 48,544 $ 242,027 Total liabilities $ 56,407 $ 3,827 $ 35,716 $ 95,950 |
Summary of Significant Accoun54
Summary of Significant Accounting Policies (Narrative) (Details) | 12 Months Ended |
Dec. 31, 2015USD ($)yr | |
Summary Of Significant Accounting Policies 1 | 50.00% |
Summary Of Significant Accounting Policies 2 | $ 35,000,000 |
Summary Of Significant Accounting Policies 3 | $ 9,900,000 |
Summary Of Significant Accounting Policies 4 | yr | 20 |
Summary Of Significant Accounting Policies 5 | $ 200,000 |
Summary Of Significant Accounting Policies 6 | $ 0.01 |
Acquisitions and Business Com55
Acquisitions and Business Combinations (Narrative) (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2015USD ($)moshares | |
Acquisitions And Business Combinations 1 | 32.14% |
Acquisitions And Business Combinations 2 | 31.78% |
Acquisitions And Business Combinations 3 | 22.22% |
Acquisitions And Business Combinations 4 | $ 300 |
Acquisitions And Business Combinations 5 | shares | 431,711 |
Acquisitions And Business Combinations 6 | $ 1,400 |
Acquisitions And Business Combinations 7 | $ 700 |
Acquisitions And Business Combinations 8 | 51.00% |
Acquisitions And Business Combinations 9 | 49.00% |
Acquisitions And Business Combinations 10 | $ 7,500 |
Acquisitions And Business Combinations 11 | 49.00% |
Acquisitions And Business Combinations 12 | $ 600 |
Acquisitions And Business Combinations 13 | 49.00% |
Acquisitions And Business Combinations 14 | $ 31,200 |
Acquisitions And Business Combinations 15 | 3,000 |
Acquisitions And Business Combinations 16 | $ 12,000 |
Acquisitions And Business Combinations 17 | shares | 6,666,666 |
Acquisitions And Business Combinations 18 | shares | 4,666,666 |
Acquisitions And Business Combinations 19 | 18.00% |
Acquisitions And Business Combinations 20 | 30.00% |
Acquisitions And Business Combinations 21 | $ 19,000 |
Acquisitions And Business Combinations 22 | 55.00% |
Acquisitions And Business Combinations 23 | $ 1,400 |
Acquisitions And Business Combinations 24 | $ 16,000 |
Acquisitions And Business Combinations 25 | 45.00% |
Acquisitions And Business Combinations 26 | $ 12,500 |
Acquisitions And Business Combinations 27 | $ 1,500 |
Acquisitions And Business Combinations 28 | 100.00% |
Acquisitions And Business Combinations 29 | $ 900 |
Acquisitions And Business Combinations 30 | 700 |
Acquisitions And Business Combinations 31 | $ 500 |
Acquisitions And Business Combinations 32 | mo | 12 |
Acquisitions And Business Combinations 33 | 0 |
Acquisitions And Business Combinations 34 | $ 100 |
Acquisitions And Business Combinations 35 | 1,400 |
Acquisitions And Business Combinations 36 | 200 |
Acquisitions And Business Combinations 37 | 1,000 |
Acquisitions And Business Combinations 38 | 1,300 |
Acquisitions And Business Combinations 39 | 27,400 |
Acquisitions And Business Combinations 40 | 9,600 |
Acquisitions And Business Combinations 41 | $ 2,600 |
Acquisitions And Business Combinations 42 | 60.00% |
Acquisitions And Business Combinations 43 | $ 3,200 |
Acquisitions And Business Combinations 44 | 60.00% |
Acquisitions And Business Combinations 45 | $ 6,900 |
Acquisitions And Business Combinations 46 | 800 |
Acquisitions And Business Combinations 47 | $ 400 |
Acquisitions And Business Combinations 48 | 100.00% |
Investments in Associates (Narr
Investments in Associates (Narrative) (Details) $ in Millions | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Investments In Associates 1 | 40.00% |
Investments In Associates 2 | $ 0.2 |
Investments In Associates 3 | 87.50% |
Investments In Associates 4 | 15.70% |
Investments In Associates 5 | 10.70% |
Investments In Associates 6 | $ 0.7 |
Investments In Associates 7 | 0.7 |
Investments In Associates 8 | 0.7 |
Investments In Associates 9 | 0.8 |
Investments In Associates 10 | 0.7 |
Investments In Associates 11 | $ 0.8 |
Financial Instruments and Con57
Financial Instruments and Concentration (Narrative) (Details) $ in Millions | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Financial Instruments And Concentration 1 | 86.00% |
Financial Instruments And Concentration 2 | 85.00% |
Financial Instruments And Concentration 3 | $ 0.3 |
Financial Instruments And Concentration 4 | $ 0.1 |
Trade Accounts Receivable, ne58
Trade Accounts Receivable, net (Narrative) (Details) | 12 Months Ended |
Dec. 31, 2015USD ($)d | |
Trade Accounts Receivable, Net 1 | $ 3,600,000 |
Trade Accounts Receivable, Net 2 | 0 |
Trade Accounts Receivable, Net 3 | 300,000 |
Trade Accounts Receivable, Net 4 | 900,000 |
Trade Accounts Receivable, Net 5 | 1,700,000 |
Trade Accounts Receivable, Net 6 | 1,000,000 |
Trade Accounts Receivable, Net 7 | 7,600,000 |
Trade Accounts Receivable, Net 8 | $ 7,300,000 |
Trade Accounts Receivable, Net 9 | d | 45 |
Trade Accounts Receivable, Net 10 | 100.00% |
Trade Accounts Receivable, Net 11 | $ 10,800,000 |
Trade Accounts Receivable, Net 12 | 1,600,000 |
Trade Accounts Receivable, Net 13 | 6,200,000 |
Trade Accounts Receivable, Net 14 | 900,000 |
Trade Accounts Receivable, Net 15 | 2,000,000 |
Trade Accounts Receivable, Net 16 | $ 1,700,000 |
Trade Accounts Receivable, Net 17 | d | 30 |
Trade Accounts Receivable, Net 18 | 100.00% |
Trade Accounts Receivable, Net 19 | $ 500,000 |
Trade Accounts Receivable, Net 20 | 300,000 |
Trade Accounts Receivable, Net 21 | $ 600,000 |
Trade Accounts Receivable, Net 22 | d | 45 |
Trade Accounts Receivable, Net 23 | 100.00% |
Trade Accounts Receivable, Net 24 | $ 200,000 |
Trade Accounts Receivable, Net 25 | 100,000 |
Trade Accounts Receivable, Net 26 | $ 200,000 |
Property and Equipment, net (Na
Property and Equipment, net (Narrative) (Details) $ in Millions | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Property And Equipment, Net 1 | $ 3.7 |
Property And Equipment, Net 2 | $ 1.6 |
Intangible Assets (Narrative) (
Intangible Assets (Narrative) (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Intangible Assets 1 | $ 900,000 |
Intangible Assets 2 | 0.2 |
Intangible Assets 3 | 1,300,000 |
Intangible Assets 4 | 1,000,000 |
Intangible Assets 5 | 5,100,000 |
Intangible Assets 6 | 300,000 |
Intangible Assets 7 | $ 2,100,000 |
Other long-term liabilities (Na
Other long-term liabilities (Narrative) (Details) $ in Millions | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Other Long-term Liabilities 1 | $ 3.3 |
Other Long-term Liabilities 2 | 0.3 |
Other Long-term Liabilities 3 | 0.3 |
Other Long-term Liabilities 4 | $ 2.1 |
Lines of Credit (Narrative) (De
Lines of Credit (Narrative) (Details) $ in Millions | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Lines Of Credit 1 | $ 5 |
Lines Of Credit 2 | 4.00% |
Lines Of Credit 3 | 4.70% |
Lines Of Credit 4 | 100.00% |
Lines Of Credit 5 | $ 3 |
Lines Of Credit 6 | 1.5 |
Lines Of Credit 7 | $ 5 |
Debt (Narrative) (Details)
Debt (Narrative) (Details) | 12 Months Ended |
Dec. 31, 2015USD ($)d | |
Debt 1 | $ 2,100,000 |
Debt 2 | $ 1,700,000 |
Debt 3 | 5.25% |
Debt 4 | 6.25% |
Debt 5 | $ 400,000 |
Debt 6 | 6.25% |
Debt 7 | $ 20,000,000 |
Debt 8 | $ 500,000 |
Debt 9 | 4.00% |
Debt 10 | $ 20,000,000 |
Debt 11 | 12.00% |
Debt 12 | $ 600,000 |
Debt 13 | 20,000,000 |
Debt 14 | $ 900,000 |
Debt 15 | 5.50% |
Debt 16 | $ 0 |
Debt 17 | $ 800,000 |
Debt 18 | 3.65% |
Debt 19 | $ 0 |
Debt 20 | $ 12,000,000 |
Debt 21 | 20 |
Debt 22 | $ 1,000,000 |
Debt 23 | 1,000,000 |
Debt 24 | $ 300,000 |
Debt 25 | 11.00% |
Debt 26 | $ 1,000,000 |
Debt 27 | 20,000,000 |
Debt 28 | $ 20,000,000 |
Debt 29 | 4.00% |
Debt 30 | 4.70% |
Debt 31 | 0.70215% |
Debt 32 | 100.00% |
Debt 33 | $ 20,000,000 |
Debt 34 | 600,000 |
Debt 35 | $ 19,100,000 |
Debt 35 | 2 |
Debt 36 | 2.25 |
Debt 37 | $ 1,000,000 |
Debt 38 | 55.00% |
Debt 39 | $ 6,100,000 |
Debt 40 | $ 4,500,000 |
Debt 41 | 4.00% |
Debt 42 | 4.425% |
Debt 44 | $ 4,200,000 |
Debt 43 | 1.05 |
Debt 44 | 1 |
Debt 45 | d | 30 |
Operating Leases (Narrative) (D
Operating Leases (Narrative) (Details) $ in Millions | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Operating Leases 1 | $ 9.1 |
Operating Leases 2 | $ 3.5 |
Capital Leases (Narrative) (Det
Capital Leases (Narrative) (Details) $ in Millions | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Capital Leases 1 | $ 7.2 |
Capital Leases 2 | 0.7 |
Capital Leases 3 | 1.7 |
Capital Leases 4 | $ 0.1 |
Shareholders Equity (Narrative)
Shareholders Equity (Narrative) (Details) - 12 months ended Dec. 31, 2015 | USD ($)shares | CADshares |
Shareholders Equity 1 | 73,675,979 | 73,675,979 |
Shareholders Equity 2 | 59,418,227 | 59,418,227 |
Shareholders Equity 3 | 5,862,500 | 5,862,500 |
Shareholders Equity 4 | CAD | CAD 0.80 | |
Shareholders Equity 5 | $ 0.76 | |
Shareholders Equity 6 | CAD | CAD 1.10 | |
Shareholders Equity 7 | $ 1.04 | |
Shareholders Equity 8 | shares | 410,375 | 410,375 |
Shareholders Equity 9 | CAD | CAD 0.95 | |
Shareholders Equity 10 | $ 0.90 | |
Shareholders Equity 11 | 4,100,000 | |
Shareholders Equity 12 | 400,000 | |
Shareholders Equity 13 | 4,100,000 | |
Shareholders Equity 14 | 2,900,000 | |
Shareholders Equity 15 | 1,200,000 | |
Shareholders Equity 16 | CAD | 1.10 | |
Shareholders Equity 17 | 1.04 | |
Shareholders Equity 18 | CAD | CAD 3.2 | |
Shareholders Equity 19 | $ 2,900,000 | |
Shareholders Equity 20 | 5,568,400 | 5,568,400 |
Shareholders Equity 21 | CAD | CAD 1.30 | |
Shareholders Equity 22 | $ 1.17 | |
Shareholders Equity 23 | CAD | CAD 1.80 | |
Shareholders Equity 24 | $ 1.62 | |
Shareholders Equity 25 | shares | 389,788 | 389,788 |
Shareholders Equity 26 | CAD | CAD 1.37 | |
Shareholders Equity 27 | $ 1.23 | |
Shareholders Equity 28 | 6,100,000 | |
Shareholders Equity 29 | 400,000 | |
Shareholders Equity 30 | 6,100,000 | |
Shareholders Equity 31 | 2,100,000 | |
Shareholders Equity 32 | $ 4,000,000 | |
Shareholders Equity 33 | shares | 6,666,666 | 6,666,666 |
Shareholders Equity 34 | shares | 4,666,666 | 4,666,666 |
Shareholders Equity 35 | 836,029 | 836,029 |
Shareholders Equity 36 | $ 2,700,000 | |
Shareholders Equity 37 | $ 1,700,000 | |
Shareholders Equity 38 | 3,830,638 | 3,830,638 |
Shareholders Equity 39 | $ 5,700,000 | |
Shareholders Equity 40 | 7,847,668 | 7,847,668 |
Shareholders Equity 41 | CAD | CAD 9 | |
Shareholders Equity 42 | $ 7.46 | |
Shareholders Equity 43 | CAD | CAD 11.50 | |
Shareholders Equity 44 | 9.54 | |
Shareholders Equity 45 | 28,400,000 | |
Shareholders Equity 46 | $ 1,900,000 | |
Shareholders Equity 47 | shares | 392,383 | 392,383 |
Shareholders Equity 48 | CAD | CAD 9 | |
Shareholders Equity 49 | $ 7.46 |
Share Based Compensation (Narra
Share Based Compensation (Narrative) (Details) | 12 Months Ended |
Dec. 31, 2015USD ($)yrdshares | |
Share Based Compensation 1 | d | 90 |
Share Based Compensation 2 | $ 5,400,000 |
Share Based Compensation 3 | $ 300,000 |
Share Based Compensation 4 | 2,000,000 |
Share Based Compensation 5 | yr | 10 |
Share Based Compensation 6 | d | 90 |
Share Based Compensation 7 | 20.00% |
Share Based Compensation 8 | shares | 3,166,782 |
Share Based Compensation 9 | 451,782 |
Share Based Compensation 10 | 450,000 |
Share Based Compensation 11 | 1,865,000 |
Share Based Compensation 12 | 400,000 |
Share Based Compensation 13 | shares | 8,300,000 |
Share Based Compensation 14 | shares | 710,000 |
Share Based Compensation 15 | 650,000 |
Share Based Compensation 16 | $ 2,100,000 |
Share Based Compensation 17 | 600,000 |
Share Based Compensation 18 | 1,800,000 |
Share Based Compensation 19 | 4,100,000 |
Share Based Compensation 20 | 6,100,000 |
Share Based Compensation 21 | $ 700,000 |
Warrants and Options Liabilit68
Warrants and Options Liabilities (Narrative) (Details) $ in Millions | 12 Months Ended |
Dec. 31, 2015USD ($)shares | |
Warrants And Options Liabilities 1 | shares | 650,000 |
Warrants And Options Liabilities 2 | $ 1.7 |
Warrants And Options Liabilities 3 | $ 0.8 |
Noncontrolling Interests (Res69
Noncontrolling Interests (Restated) (Narrative) (Details) | 12 Months Ended |
Dec. 31, 2015 | |
Noncontrolling Interests (restated) 1 | 8.10% |
Noncontrolling Interests (restated) 2 | 75.00% |
Noncontrolling Interests (restated) 3 | 5.00% |
Noncontrolling Interests (restated) 4 | 2.30% |
Noncontrolling Interests (restated) 5 | 60.00% |
Noncontrolling Interests (restated) 6 | 50.00% |
Noncontrolling Interests (restated) 7 | 60.00% |
Noncontrolling Interests (restated) 8 | 49.00% |
Noncontrolling Interests (restated) 9 | 40.00% |
Noncontrolling Interests (restated) 10 | 45.00% |
Noncontrolling Interests (restated) 11 | 40.00% |
Employee Retirement Plan (Narra
Employee Retirement Plan (Narrative) (Details) $ in Millions | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Employee Retirement Plan 1 | $ 0.4 |
Employee Retirement Plan 2 | $ 0.1 |
Earnings per Share (Restated)71
Earnings per Share (Restated) (Narrative) (Details) pure in Millions | 12 Months Ended |
Dec. 31, 2015 | |
Employee Retirement Plan 3 | 12.4 |
Income Taxes (Narrative) (Detai
Income Taxes (Narrative) (Details) $ in Millions | 12 Months Ended |
Dec. 31, 2015USD ($)shares | |
Income Taxes 1 | 34.00% |
Income Taxes 2 | $ 9.6 |
Income Taxes 2 | 29.6 |
Income Taxes 3 | $ 15.6 |
Income Taxes 4 | shares | 18,778,446 |
Income Taxes 5 | 50.00% |
Income Taxes 6 | $ 4 |
Related Parties (Narrative) (De
Related Parties (Narrative) (Details) - 12 months ended Dec. 31, 2015 $ in Thousands | USD ($)shares | CADshares |
Related Parties 1 | $ 20,000 | |
Related Parties 2 | $ 200 | |
Related Parties 3 | 5.50% | 5.50% |
Related Parties 4 | $ 700 | |
Related Parties 5 | 400 | |
Related Parties 6 | 200 | |
Related Parties 7 | 200 | |
Related Parties 8 | 2,300 | |
Related Parties 9 | 600 | |
Related Parties 10 | 12,000 | |
Related Parties 11 | 20,000 | |
Related Parties 12 | $ 900 | |
Related Parties 13 | 10.00% | 10.00% |
Related Parties 14 | shares | 7,847,668 | 7,847,668 |
Related Parties 15 | CAD | CAD 9 | |
Related Parties 16 | CAD | 70,600,000 | |
Related Parties 17 | CAD | CAD 34,400,000 | |
Related Parties 18 | $ 100 | |
Related Parties 19 | 3,000 | |
Related Parties 20 | 300 | |
Related Parties 21 | $ 1,200 | |
Related Parties 22 | 600,000 | 600,000 |
Related Parties 23 | $ 300 | |
Related Parties 24 | 3,100 | |
Related Parties 25 | $ 1,000 |
Commitments and Contingencies (
Commitments and Contingencies (Narrative) (Details) - 12 months ended Dec. 31, 2015 CAD in Millions, $ in Millions | USD ($) | CAD |
Commitments And Contingencies 1 | $ | $ 0.3 | |
Commitments And Contingencies 5 | CAD | CAD 80 |
Subsequent Events (Narrative) (
Subsequent Events (Narrative) (Details) $ in Millions | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Subsequent Events 1 | $ 1 |
Subsequent Events 2 | 3 |
Subsequent Events 3 | $ 16 |
Schedule of Cash Flow, Suppleme
Schedule of Cash Flow, Supplemental Disclosures (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 1 | $ 1,236 |
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 2 | 165 |
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 3 | 427 |
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 4 | 216 |
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 5 | 28,373 |
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 6 | 2,271 |
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 7 | 24,641 |
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 8 | 7,206 |
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 9 | 2,828 |
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 10 | 0 |
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 11 | 701 |
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 12 | 0 |
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 13 | 0 |
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 14 | 696 |
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 15 | 650 |
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 16 | 0 |
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 17 | 5,685 |
Supplemental Cash Flow Information Schedule Of Cash Flow, Supplemental Disclosures 18 | $ 0 |
Schedule of Fair Value of Ident
Schedule of Fair Value of Identifiable Assets (Details) - USD ($) | 1 Months Ended | ||||||
Nov. 30, 2015 | Jul. 31, 2015 | Jun. 30, 2015 | Apr. 30, 2015 | Dec. 31, 2014 | Sep. 30, 2014 | Jan. 31, 2014 | |
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 1 | $ 563 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 2 | 48 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 3 | 2,271 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 4 | 40 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 5 | 701 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 6 | 3,623 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 7 | 697 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 8 | 1,544 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 9 | 2,241 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 10 | 346 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 11 | 514 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 12 | 522 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 13 | $ 1,382 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 1 | $ 6,509 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 2 | 598 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 3 | 1,000 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 4 | 2,800 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 5 | 649 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 6 | 11,556 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 7 | 6,060 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 8 | 290 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 9 | $ 6,350 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 10 | 49.00% | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 11 | $ 5,206 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 1 | $ (53) | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 2 | 4,713 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 3 | 450 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 4 | 226 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 5 | 730 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 6 | 752 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 7 | 5,610 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 8 | 1,980 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 9 | 1,920 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 10 | 5,620 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 11 | 19,011 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 12 | 40,959 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 13 | 1,531 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 14 | 2,915 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 15 | 4,120 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 16 | 635 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 17 | 157 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 18 | 102 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 19 | 260 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 20 | 9,720 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 21 | 3,000 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 22 | 12,000 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 23 | 16,239 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 24 | $ 31,239 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 1 | $ 64 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 2 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 3 | 64 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 4 | 2,500 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 5 | (364) | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 6 | 2,136 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 7 | 6,325 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 8 | (5,907) | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 9 | 418 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 10 | 44 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 11 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 12 | 44 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 13 | 662 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 14 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 15 | 662 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 16 | 4,860 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 17 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 18 | 4,860 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 19 | 2 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 20 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 21 | 2 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 22 | 280 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 23 | (280) | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 24 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 25 | 940 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 26 | (940) | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 27 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 28 | 13 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 29 | (1) | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 30 | 12 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 31 | 9,447 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 32 | 6,592 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 33 | 16,039 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 34 | 25,137 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 35 | (900) | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 36 | 24,237 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 37 | 6,266 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 38 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 39 | 6,266 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 40 | 3,198 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 41 | (708) | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 42 | 2,490 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 43 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 44 | 2,740 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 45 | 2,740 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 46 | 2,278 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 47 | 168 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 48 | 2,446 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 49 | 6,052 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 50 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 51 | 6,052 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 52 | 17,794 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 53 | 2,200 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 54 | 19,994 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 55 | 1,436 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 56 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 57 | 1,436 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 58 | 5,907 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 59 | (5,907) | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 60 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 61 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 62 | 2,807 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 63 | 2,807 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 64 | 7,343 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 65 | (3,100) | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 66 | $ 4,243 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 1 | $ 1 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 2 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 3 | 1 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 4 | 315 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 5 | 54 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 6 | 369 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 7 | 4 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 8 | (4) | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 9 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 10 | 315 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 11 | (238) | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 12 | 77 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 13 | 500 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 14 | 500 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 15 | 1,318 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 16 | (344) | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 17 | 974 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 18 | 1,953 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 19 | (32) | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 20 | 1,921 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 21 | 138 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 22 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 23 | 138 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 24 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 25 | 107 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 26 | 107 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 27 | 315 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 28 | (238) | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 29 | 77 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 30 | 453 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 31 | (131) | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 32 | 322 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 33 | 850 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 34 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 35 | 850 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 36 | 650 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 37 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 38 | 650 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 39 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 40 | 99 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 41 | 99 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 42 | 1,500 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 43 | 99 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 44 | $ 1,599 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 1 | $ 3,000 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 2 | (1,500) | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 3 | 1,500 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 4 | 881 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 5 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 6 | 881 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 7 | 10,170 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 8 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 9 | 10,170 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 10 | 13 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 11 | (1) | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 12 | 12 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 13 | 14,064 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 14 | (1,501) | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 15 | 12,563 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 16 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 17 | 3,907 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 18 | 281 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 19 | 4,188 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 20 | 4,500 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 21 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 22 | 4,500 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 23 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 24 | 843 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 25 | 843 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 26 | 8,407 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 27 | 1,124 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 28 | 9,531 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 29 | 1,299 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 30 | 0 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 31 | 1,299 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 32 | 4,358 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 33 | (2,625) | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 34 | $ 1,733 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 1 | $ 82 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 2 | 36 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 3 | 69 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 4 | 13,266 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 5 | 113 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 6 | 6,932 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 7 | 160 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 8 | 12 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 9 | 20,670 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 10 | 2,668 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 11 | 419 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 12 | 1,510 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 13 | 11,361 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 14 | 15,958 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 15 | 3,180 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 16 | 1,532 | ||||||
Acquisitions And Business Combinations Schedule Of Fair Value Of Identifiable Assets 17 | $ 4,712 |
Business Acquisition, Pro Forma
Business Acquisition, Pro Forma Information (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Acquisitions And Business Combinations Set Schedule Title Here 1 | $ 233,581 |
Acquisitions And Business Combinations Set Schedule Title Here 2 | 133,987 |
Acquisitions And Business Combinations Set Schedule Title Here 3 | 24,592 |
Acquisitions And Business Combinations Set Schedule Title Here 4 | 19,399 |
Acquisitions And Business Combinations Set Schedule Title Here 5 | 10,216 |
Acquisitions And Business Combinations Set Schedule Title Here 6 | 13,593 |
Acquisitions And Business Combinations Set Schedule Title Here 7 | 46,567 |
Acquisitions And Business Combinations Set Schedule Title Here 8 | $ 1,326 |
Acquisitions And Business Combinations Set Schedule Title Here 9 | 0.69 |
Acquisitions And Business Combinations Set Schedule Title Here 10 | 0.02 |
Schedule of Revenue by Major Cu
Schedule of Revenue by Major Customers by Reporting Segments (Details) | 12 Months Ended |
Dec. 31, 2015 | |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 1 | 95.60% |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 2 | 97.10% |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 3 | 4.00% |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 4 | 2.20% |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 5 | 0.40% |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 6 | 0.70% |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 7 | 100.00% |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 8 | 100.00% |
Medical services [Member] | |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 1 | 95.50% |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 2 | 97.00% |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 3 | 4.10% |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 4 | 2.30% |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 5 | 0.40% |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 6 | 0.70% |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 7 | 100.00% |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 8 | 100.00% |
Marketing & Factoring [Member] | |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 1 | 100.00% |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 2 | 100.00% |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 3 | 0.00% |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 4 | 0.00% |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 5 | 0.00% |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 6 | 0.00% |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 7 | 100.00% |
Financial Instruments And Concentration Schedule Of Revenue By Major Customers By Reporting Segments 8 | 100.00% |
Schedule of Accounts, Notes, Lo
Schedule of Accounts, Notes, Loans and Financing Receivable (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Trade Accounts Receivable, Net Schedule Of Accounts, Notes, Loans And Financing Receivable 1 | $ 95,114 |
Trade Accounts Receivable, Net Schedule Of Accounts, Notes, Loans And Financing Receivable 2 | 40,985 |
Trade Accounts Receivable, Net Schedule Of Accounts, Notes, Loans And Financing Receivable 3 | (5,165) |
Trade Accounts Receivable, Net Schedule Of Accounts, Notes, Loans And Financing Receivable 4 | (1,391) |
Trade Accounts Receivable, Net Schedule Of Accounts, Notes, Loans And Financing Receivable 5 | (298) |
Trade Accounts Receivable, Net Schedule Of Accounts, Notes, Loans And Financing Receivable 6 | (873) |
Trade Accounts Receivable, Net Schedule Of Accounts, Notes, Loans And Financing Receivable 7 | 2,918 |
Trade Accounts Receivable, Net Schedule Of Accounts, Notes, Loans And Financing Receivable 8 | 1,740 |
Trade Accounts Receivable, Net Schedule Of Accounts, Notes, Loans And Financing Receivable 9 | 92,569 |
Trade Accounts Receivable, Net Schedule Of Accounts, Notes, Loans And Financing Receivable 10 | $ 40,461 |
Schedule of Property, Plant and
Schedule of Property, Plant and Equipment (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 1 | $ 122 |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 2 | 51 |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 3 | 780 |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 4 | 510 |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 5 | 733 |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 6 | 569 |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 7 | 1,143 |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 8 | 920 |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 9 | 23,482 |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 10 | 9,947 |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 11 | 7,942 |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 12 | 6,290 |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 13 | 12,520 |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 14 | 0 |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 15 | 1,325 |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 16 | 0 |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 17 | 48,047 |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 18 | 18,287 |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 19 | (12,744) |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 20 | (9,200) |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 21 | 35,303 |
Property And Equipment, Net Schedule Of Property, Plant And Equipment 22 | $ 9,087 |
Schedule of Finite-Lived Intang
Schedule of Finite-Lived Intangible Assets (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Intangible Assets Schedule Of Finite-lived Intangible Assets 1 | $ 2,761 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 2 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 3 | 993 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 4 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 5 | 1,768 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 6 | 2,765 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 7 | 857 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 8 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 9 | 1,908 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 10 | 1,980 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 11 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 12 | 330 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 13 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 14 | 1,650 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 15 | 1,980 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 16 | 33 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 17 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 18 | 1,947 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 19 | 5,620 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 20 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 21 | 468 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 22 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 23 | 5,152 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 24 | 5,620 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 25 | 47 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 26 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 27 | 5,573 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 28 | 2,800 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 29 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 30 | 130 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 31 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 32 | 2,670 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 33 | 2,800 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 34 | 47 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 35 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 36 | 2,753 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 37 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 38 | 500 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 39 | 24 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 40 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 41 | 476 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 42 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 43 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 44 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 45 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 46 | 1,000 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 47 | 160 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 48 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 49 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 50 | 1,160 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 51 | 1,000 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 52 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 53 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 54 | 1,000 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 55 | 5,610 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 56 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 57 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 58 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 59 | 5,610 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 60 | 5,610 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 61 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 62 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 63 | 5,610 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 64 | 8,498 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 65 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 66 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 67 | 7,401 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 68 | 1,097 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 69 | 8,498 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 70 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 71 | 7,401 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 72 | 1,097 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 73 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 74 | 36 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 75 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 76 | 0 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 77 | 36 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 78 | 28,269 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 79 | 696 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 80 | 1,945 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 81 | 7,401 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 82 | 19,619 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 83 | 28,273 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 84 | 984 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 85 | 7,401 |
Intangible Assets Schedule Of Finite-lived Intangible Assets 86 | $ 19,888 |
Goodwill Cost and Impairment Lo
Goodwill Cost and Impairment Losses (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Goodwill Set Schedule Title Here 1 | $ 183,276 |
Goodwill Set Schedule Title Here 2 | 160,032 |
Goodwill Set Schedule Title Here 3 | (138,443) |
Goodwill Set Schedule Title Here 4 | (138,443) |
Goodwill Set Schedule Title Here 5 | 44,833 |
Goodwill Set Schedule Title Here 6 | $ 21,589 |
Schedule of Goodwill (Details)
Schedule of Goodwill (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Goodwill Schedule Of Goodwill 1 | $ 160,032 |
Goodwill Schedule Of Goodwill 2 | 139,671 |
Goodwill Schedule Of Goodwill 3 | 0 |
Goodwill Schedule Of Goodwill 4 | 701 |
Goodwill Schedule Of Goodwill 5 | 0 |
Goodwill Schedule Of Goodwill 6 | 649 |
Goodwill Schedule Of Goodwill 7 | 0 |
Goodwill Schedule Of Goodwill 8 | 19,011 |
Goodwill Schedule Of Goodwill 9 | (701) |
Goodwill Schedule Of Goodwill 10 | 0 |
Goodwill Schedule Of Goodwill 11 | 16,039 |
Goodwill Schedule Of Goodwill 12 | 0 |
Goodwill Schedule Of Goodwill 13 | 974 |
Goodwill Schedule Of Goodwill 14 | 0 |
Goodwill Schedule Of Goodwill 15 | 6,932 |
Goodwill Schedule Of Goodwill 16 | 183,276 |
Goodwill Schedule Of Goodwill 17 | 160,032 |
Goodwill Schedule Of Goodwill 18 | (138,443) |
Goodwill Schedule Of Goodwill 19 | (138,443) |
Goodwill Schedule Of Goodwill 20 | 0 |
Goodwill Schedule Of Goodwill 21 | 0 |
Goodwill Schedule Of Goodwill 22 | (138,443) |
Goodwill Schedule Of Goodwill 23 | $ (138,443) |
Schedule of Accounts Payable an
Schedule of Accounts Payable and Accrued Liabilities (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Accrued Expenses And Other Current Liabilities Schedule Of Accounts Payable And Accrued Liabilities 1 | $ 5,309 |
Accrued Expenses And Other Current Liabilities Schedule Of Accounts Payable And Accrued Liabilities 2 | 684 |
Accrued Expenses And Other Current Liabilities Schedule Of Accounts Payable And Accrued Liabilities 3 | 11,339 |
Accrued Expenses And Other Current Liabilities Schedule Of Accounts Payable And Accrued Liabilities 4 | 7,874 |
Accrued Expenses And Other Current Liabilities Schedule Of Accounts Payable And Accrued Liabilities 5 | 16,648 |
Accrued Expenses And Other Current Liabilities Schedule Of Accounts Payable And Accrued Liabilities 6 | 8,558 |
Accrued Expenses And Other Current Liabilities Schedule Of Accounts Payable And Accrued Liabilities 7 | 3,795 |
Accrued Expenses And Other Current Liabilities Schedule Of Accounts Payable And Accrued Liabilities 8 | 0 |
Accrued Expenses And Other Current Liabilities Schedule Of Accounts Payable And Accrued Liabilities 9 | 1,230 |
Accrued Expenses And Other Current Liabilities Schedule Of Accounts Payable And Accrued Liabilities 10 | 1,508 |
Accrued Expenses And Other Current Liabilities Schedule Of Accounts Payable And Accrued Liabilities 11 | 5,025 |
Accrued Expenses And Other Current Liabilities Schedule Of Accounts Payable And Accrued Liabilities 12 | $ 1,508 |
Schedule of Long-term Debt Inst
Schedule of Long-term Debt Instruments (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Debt Schedule Of Long-term Debt Instruments 1 | $ 26,275 |
Debt Schedule Of Long-term Debt Instruments 2 | 20,074 |
Debt Schedule Of Long-term Debt Instruments 3 | 563 |
Debt Schedule Of Long-term Debt Instruments 4 | 0 |
Debt Schedule Of Long-term Debt Instruments 5 | 25,712 |
Debt Schedule Of Long-term Debt Instruments 6 | 20,074 |
Debt Schedule Of Long-term Debt Instruments 7 | 1,243 |
Debt Schedule Of Long-term Debt Instruments 8 | 3,437 |
Debt Schedule Of Long-term Debt Instruments 9 | 0 |
Debt Schedule Of Long-term Debt Instruments 10 | 635 |
Debt Schedule Of Long-term Debt Instruments 11 | 3,000 |
Debt Schedule Of Long-term Debt Instruments 12 | 5,420 |
Debt Schedule Of Long-term Debt Instruments 13 | 21,469 |
Debt Schedule Of Long-term Debt Instruments 14 | $ 10,582 |
Schedule of Maturities of Long-
Schedule of Maturities of Long-term Debt (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Debt Schedule Of Maturities Of Long-term Debt 1 | $ 1,375 |
Debt Schedule Of Maturities Of Long-term Debt 2 | 1,900 |
Debt Schedule Of Maturities Of Long-term Debt 3 | 1,900 |
Debt Schedule Of Maturities Of Long-term Debt 4 | 1,900 |
Debt Schedule Of Maturities Of Long-term Debt 5 | 19,200 |
Debt Schedule Of Maturities Of Long-term Debt 6 | $ 26,275 |
Schedule of Future Minimum Rent
Schedule of Future Minimum Rental Payments for Operating Leases (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Operating Leases Schedule Of Future Minimum Rental Payments For Operating Leases 1 | $ 10,648 |
Operating Leases Schedule Of Future Minimum Rental Payments For Operating Leases 2 | 10,132 |
Operating Leases Schedule Of Future Minimum Rental Payments For Operating Leases 3 | 9,742 |
Operating Leases Schedule Of Future Minimum Rental Payments For Operating Leases 4 | 9,263 |
Operating Leases Schedule Of Future Minimum Rental Payments For Operating Leases 5 | 7,361 |
Operating Leases Schedule Of Future Minimum Rental Payments For Operating Leases 6 | 45,457 |
Operating Leases Schedule Of Future Minimum Rental Payments For Operating Leases 7 | 92,603 |
Operating Leases Schedule Of Future Minimum Rental Payments For Operating Leases 8 | (571) |
Operating Leases Schedule Of Future Minimum Rental Payments For Operating Leases 9 | $ 92,032 |
Schedule of Future Minimum Leas
Schedule of Future Minimum Lease Payments for Capital Leases (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Capital Leases Schedule Of Future Minimum Lease Payments For Capital Leases 1 | $ 5,193 |
Capital Leases Schedule Of Future Minimum Lease Payments For Capital Leases 2 | 4,327 |
Capital Leases Schedule Of Future Minimum Lease Payments For Capital Leases 3 | 2,061 |
Capital Leases Schedule Of Future Minimum Lease Payments For Capital Leases 4 | 1,820 |
Capital Leases Schedule Of Future Minimum Lease Payments For Capital Leases 5 | 1,802 |
Capital Leases Schedule Of Future Minimum Lease Payments For Capital Leases 6 | 9,465 |
Capital Leases Schedule Of Future Minimum Lease Payments For Capital Leases 7 | 24,668 |
Capital Leases Schedule Of Future Minimum Lease Payments For Capital Leases 8 | (5,821) |
Capital Leases Schedule Of Future Minimum Lease Payments For Capital Leases 9 | $ 18,847 |
Schedule of Fair Value, by Bala
Schedule of Fair Value, by Balance Sheet Grouping (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Fair Value Measurements Schedule Of Fair Value, By Balance Sheet Grouping 1 | $ 0 |
Fair Value Measurements Schedule Of Fair Value, By Balance Sheet Grouping 2 | 0 |
Fair Value Measurements Schedule Of Fair Value, By Balance Sheet Grouping 3 | 6,657 |
Fair Value Measurements Schedule Of Fair Value, By Balance Sheet Grouping 4 | 6,657 |
Fair Value Measurements Schedule Of Fair Value, By Balance Sheet Grouping 5 | 0 |
Fair Value Measurements Schedule Of Fair Value, By Balance Sheet Grouping 6 | 0 |
Fair Value Measurements Schedule Of Fair Value, By Balance Sheet Grouping 7 | 6,657 |
Fair Value Measurements Schedule Of Fair Value, By Balance Sheet Grouping 8 | 6,657 |
Fair Value Measurements Schedule Of Fair Value, By Balance Sheet Grouping 9 | 0 |
Fair Value Measurements Schedule Of Fair Value, By Balance Sheet Grouping 10 | 0 |
Fair Value Measurements Schedule Of Fair Value, By Balance Sheet Grouping 11 | 2,951 |
Fair Value Measurements Schedule Of Fair Value, By Balance Sheet Grouping 12 | 2,951 |
Fair Value Measurements Schedule Of Fair Value, By Balance Sheet Grouping 13 | 0 |
Fair Value Measurements Schedule Of Fair Value, By Balance Sheet Grouping 14 | 0 |
Fair Value Measurements Schedule Of Fair Value, By Balance Sheet Grouping 15 | 2,951 |
Fair Value Measurements Schedule Of Fair Value, By Balance Sheet Grouping 16 | $ 2,951 |
Schedule of Share-based Compens
Schedule of Share-based Compensation, Stock Options, Activity (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 1 | $ 700,000 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 2 | 0.39 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 3 | 9.8 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 4 | $ 3,068,218 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 5 | 1.47 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 6 | 9.9 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 7 | $ (600,000) |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 8 | 0.30 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 9 | $ (50,000) |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 10 | 1.31 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 11 | $ 3,118,218 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 12 | 1.45 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 13 | 9.8 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 14 | $ 220,000 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 15 | 1.16 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 16 | 9.6 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 17 | $ 3,118,218 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 18 | 1.45 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 19 | 9.8 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 20 | $ 3,166,782 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 21 | 4.13 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 22 | 9.5 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 23 | $ (447,787) |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 24 | 1.13 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 25 | $ (372,213) |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 26 | 1.01 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 27 | $ 5,465,000 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 28 | 2.97 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 29 | 9.2 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 30 | $ 2,129,522 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 31 | 2.16 |
Share Based Compensation Schedule Of Share-based Compensation, Stock Options, Activity 32 | 8.8 |
Schedule of Share-based Payment
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 1 | 113.00% |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 2 | 122.00% |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 3 | 120.00% |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 4 | 128.00% |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 5 | 1.34% |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 6 | 1.87% |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 7 | 1.73% |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 8 | 1.91% |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 9 | 0.00% |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 10 | 0.00% |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 11 | $ 5 |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 12 | 6 |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 13 | 5 |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 14 | $ 6 |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 15 | 1.30% |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 16 | 5.00% |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 17 | 0.00% |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 18 | 8.80% |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 19 | 2.53 |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 20 | $ 6.10 |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 21 | 0.86 |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 22 | $ 1.67 |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 23 | 2.97 |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 24 | $ 6.31 |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 25 | 0.97 |
Share Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 26 | $ 1.64 |
Schedule of Stockholders' Equit
Schedule of Stockholders' Equity Note, Warrants or Rights, Valuation Assumptions (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 1 | 0.00% |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 2 | 0.65% |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 3 | 0.13% |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 4 | 0.67% |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 5 | 0.25 |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 6 | $ 2 |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 7 | 1 |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 8 | $ 2 |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 9 | 71.00% |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 10 | 96.00% |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 11 | 73.00% |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 12 | 146.00% |
Schedule of Stockholders' Equ94
Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1 | $ 6,657 |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 2 | 2,401 |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 3 | 12,797 |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 4 | 2,143 |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 5 | (9,050) |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 6 | (1,608) |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 7 | (8,295) |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 8 | 3,721 |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 9 | 2,109 |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 10 | $ 6,657 |
Schedule of Disclosure of Share
Schedule of Disclosure of Share-based Compensation Arrangements by Share-based Payment Award and Warrants or Rights[Table Text Block] (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Warrants And Options Liabilities Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award And Warrants Or Right 1 | $ 1.80 |
Warrants And Options Liabilities Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award And Warrants Or Right 2 | $ 9 |
Warrants And Options Liabilities Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award And Warrants Or Right 3 | 0.75 |
Warrants And Options Liabilities Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award And Warrants Or Right 4 | $ 1.37 |
Warrants And Options Liabilities Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award And Warrants Or Right 5 | $ 117,810 |
Warrants And Options Liabilities Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award And Warrants Or Right 6 | 0.75 |
Warrants And Options Liabilities Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award And Warrants Or Right 7 | $ 11.50 |
Warrants And Options Liabilities Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award And Warrants Or Right 8 | $ 3,923,834 |
Warrants And Options Liabilities Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award And Warrants Or Right 9 | 1.40 |
Warrants And Options Liabilities Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award And Warrants Or Right 10 | $ 9 |
Warrants And Options Liabilities Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award And Warrants Or Right 11 | $ 392,383 |
Warrants And Options Liabilities Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award And Warrants Or Right 12 | 1.40 |
Warrants And Options Liabilities Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award And Warrants Or Right 13 | $ 4,434,036 |
Schedule of Stockholders' Equ96
Schedule of Stockholders' Equity Note, Option Awards, Valuation Assumptions (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Option Awards, Valuation Assumptions 1 | 0.26% |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Option Awards, Valuation Assumptions 2 | 1.85% |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Option Awards, Valuation Assumptions 3 | 0.53% |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Option Awards, Valuation Assumptions 4 | 2.00% |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Option Awards, Valuation Assumptions 5 | $ 1 |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Option Awards, Valuation Assumptions 6 | 6 |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Option Awards, Valuation Assumptions 7 | 2 |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Option Awards, Valuation Assumptions 8 | $ 6 |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Option Awards, Valuation Assumptions 9 | 74.00% |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Option Awards, Valuation Assumptions 10 | 121.00% |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Option Awards, Valuation Assumptions 11 | 113.00% |
Warrants And Options Liabilities Schedule Of Stockholders' Equity Note, Option Awards, Valuation Assumptions 12 | 127.00% |
Redeemable Noncontrolling Inter
Redeemable Noncontrolling Interest (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 1 | $ 1,263 |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 2 | 0 |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 3 | 1,263 |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 4 | 5,206 |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 5 | 5,206 |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 6 | (2,846) |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 7 | 0 |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 8 | (2,846) |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 9 | 8,237 |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 10 | 1,007 |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 11 | 9,244 |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 12 | 6,654 |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 13 | 6,213 |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 14 | 12,867 |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 15 | 6,654 |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 16 | 6,213 |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 17 | 12,867 |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 18 | (3,892) |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 19 | (7,617) |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 20 | (11,509) |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 21 | 631 |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 22 | 10,236 |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 23 | 10,867 |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 24 | 3,393 |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 25 | 8,832 |
Noncontrolling Interests (restated) Redeemable Noncontrolling Interest 26 | $ 12,225 |
Schedule of Earnings Per Share,
Schedule of Earnings Per Share, Basic and Diluted (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Employee Retirement Plan Schedule Of Earnings Per Share, Basic And Diluted 1 | $ 50,840 |
Employee Retirement Plan Schedule Of Earnings Per Share, Basic And Diluted 2 | 2,893 |
Employee Retirement Plan Schedule Of Earnings Per Share, Basic And Diluted 3 | 67,015,387 |
Employee Retirement Plan Schedule Of Earnings Per Share, Basic And Diluted 4 | $ 46,517,815 |
Employee Retirement Plan Schedule Of Earnings Per Share, Basic And Diluted 5 | 0.76 |
Employee Retirement Plan Schedule Of Earnings Per Share, Basic And Diluted 6 | 0.06 |
Employee Retirement Plan Schedule Of Earnings Per Share, Basic And Diluted 7 | $ 50,840 |
Employee Retirement Plan Schedule Of Earnings Per Share, Basic And Diluted 8 | 2,893 |
Employee Retirement Plan Schedule Of Earnings Per Share, Basic And Diluted 9 | 67,015,387 |
Employee Retirement Plan Schedule Of Earnings Per Share, Basic And Diluted 10 | 46,517,815 |
Employee Retirement Plan Schedule Of Earnings Per Share, Basic And Diluted 11 | 8,217,396 |
Employee Retirement Plan Schedule Of Earnings Per Share, Basic And Diluted 12 | 1,202,754 |
Employee Retirement Plan Schedule Of Earnings Per Share, Basic And Diluted 13 | 75,232,783 |
Employee Retirement Plan Schedule Of Earnings Per Share, Basic And Diluted 14 | $ 47,720,569 |
Employee Retirement Plan Schedule Of Earnings Per Share, Basic And Diluted 15 | 0.68 |
Employee Retirement Plan Schedule Of Earnings Per Share, Basic And Diluted 16 | 0.06 |
Schedule of Components of Incom
Schedule of Components of Income Tax Expense (Benefit) (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 1 | $ 8,215 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 2 | 509 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 3 | 8,724 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 4 | 0 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 5 | 1,330 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 6 | 1,330 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 7 | 0 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 8 | 0 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 9 | 0 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 10 | (33,250) |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 11 | 0 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 12 | (33,250) |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 13 | (25,035) |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 14 | 1,839 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 15 | (23,196) |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 16 | 0 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 17 | 0 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 18 | 0 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 19 | 0 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 20 | 480 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 21 | 480 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 22 | 0 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 23 | 0 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 24 | 0 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 25 | 0 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 26 | 0 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 27 | 0 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 28 | 0 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 29 | 480 |
Income Taxes Schedule Of Components Of Income Tax Expense (benefit) 30 | $ 480 |
Schedule of Effective Income Ta
Schedule of Effective Income Tax Rate Reconciliation (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 1 | $ 40,737 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 2 | $ 16,450 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 3 | 34.00% |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 4 | 34.00% |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 5 | $ 13,851 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 6 | 5,593 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 7 | (1,873) |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 8 | 388 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 9 | 649 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 10 | 317 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 11 | (33,250) |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 12 | (4,566) |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 13 | (4,106) |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 14 | (4,446) |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 15 | 1,533 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 16 | 3,194 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 17 | (23,196) |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 18 | $ 480 |
Schedule of Deferred Tax Assets
Schedule of Deferred Tax Assets and Liabilities (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 1 | $ 12,047 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 2 | 15,617 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 3 | 797 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 4 | 1,070 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 5 | 5,300 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 6 | 13,814 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 7 | 1,351 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 8 | 1,351 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 9 | 7,404 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 10 | 8,153 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 11 | 1,531 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 12 | 373 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 13 | 2,479 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 14 | 275 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 15 | 1,020 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 16 | 0 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 17 | 509 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 18 | 0 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 19 | (7,403) |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 20 | (40,653) |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 21 | 25,035 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 22 | $ 0 |
Schedule of Segment Reporting I
Schedule of Segment Reporting Information, by Segment (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 1 | $ 205,730 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 2 | 23,486 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 3 | 0 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 4 | 229,216 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 5 | 145,835 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 6 | 19,885 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 7 | 0 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 8 | 165,720 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 9 | 0 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 10 | 0 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 11 | 31,846 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 12 | 31,846 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 13 | 59,895 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 14 | 3,601 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 15 | (31,846) |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 16 | 31,650 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 17 | 351 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 18 | 54 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 19 | 1,192 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 20 | 1,597 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 21 | 0 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 22 | 0 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 23 | (8,985) |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 24 | (8,985) |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 25 | (1,733) |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 26 | 0 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 27 | 0 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 28 | (1,733) |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 29 | 488 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 30 | 236 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 31 | (690) |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 32 | 34 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 33 | 60,789 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 34 | 3,311 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 35 | (23,363) |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 36 | 40,737 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 37 | 3,403 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 38 | 1,128 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 39 | 156 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 40 | 4,687 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 41 | 898 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 42 | 238 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 43 | 703 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 44 | 1,839 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 45 | 5,462 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 46 | 14,157 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 47 | 0 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 48 | 19,619 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 49 | 25,822 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 50 | 19,011 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 51 | 0 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 52 | 44,833 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 53 | 3,653 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 54 | 249 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 55 | 478 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 56 | 4,380 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 57 | 28,373 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 58 | 0 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 59 | 0 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 60 | 28,373 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 61 | 24,641 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 62 | 0 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 63 | 0 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 64 | 24,641 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 65 | 151,324 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 66 | 42,159 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 67 | 48,544 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 68 | 242,027 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 69 | 56,407 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 70 | 3,827 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 71 | 35,716 |
Business Segment Information Schedule Of Segment Reporting Information, By Segment 72 | $ 95,950 |